

PD-1 Blockade with Pembrolizumab in Advanced Merke

New England Journal of Medicine

374, 2542-2552

DOI: [10.1056/nejmoa1603702](https://doi.org/10.1056/nejmoa1603702)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Merkel Cell Carcinoma: An Unusually Immunogenic Cancer Proves Ripe for Immune Therapy. <i>Journal of Oncology Practice</i> , 2016, 12, 649-650.	2.5	8
2	Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature. <i>Translational Lung Cancer Research</i> , 2016, 5, 720-726.	1.3	32
3	The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. <i>Frontiers in Immunology</i> , 2016, 7, 550.	2.2	409
4	The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2016, 7, 621.	2.2	132
5	Advances in Cancer Immunotherapy in Solid Tumors. <i>Cancers</i> , 2016, 8, 106.	1.7	131
6	Nursing Management of Advanced Merkel Cell Carcinoma. <i>Oncology Nursing Forum</i> , 2016, 43, 680-683.	0.5	0
7	Pembrolizumab (Keytruda). <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2777-2789.	1.4	237
8	Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas. <i>Immunotherapy</i> , 2016, 8, 907-921.	1.0	20
9	Metastatic Merkel cell carcinoma response to nivolumab. , 2016, 4, 79.		40
10	What does PD-L1 positive or negative mean?. <i>Journal of Experimental Medicine</i> , 2016, 213, 2835-2840.	4.2	263
11	The SCAR (Scar Cosmesis Assessment and Rating) scale: new evaluation method for postoperative scars. <i>British Journal of Dermatology</i> , 2016, 175, 1151-1152.	1.4	11
12	Programmed cell death protein-1 inhibitors for immunotherapy of advanced nonmelanoma skin cancer: showing early promise. <i>British Journal of Dermatology</i> , 2016, 175, 1150-1151.	1.4	7
13	Merkel Cell Carcinoma: Characteristics, Management, and What's on the Horizon. <i>Clinical Skin Cancer</i> , 2016, 1, 66-74.	0.1	1
14	Merkel cell polyomavirus and cutaneous Merkel cell carcinoma. <i>Future Science OA</i> , 2016, 2, FSO155.	0.9	2
15	Targeting T Cell Co-receptors for Cancer Therapy. <i>Immunity</i> , 2016, 44, 1069-1078.	6.6	418
16	Overcoming checkpoints in Merkel-cell carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 329-329.	12.5	1
17	Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1374-1385.	5.1	1,034
18	Checkpoint inhibitors: a new standard of care for advanced Merkel cell carcinoma?. <i>Lancet Oncology</i> , The, 2016, 17, 1337-1339.	5.1	14

#	ARTICLE	IF	CITATIONS
19	Complete spontaneous regression of Merkel cell carcinoma (1986–2016): a 30 year perspective. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 1150-1154.	0.7	41
20	The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2016, 4, 726-733.	1.6	133
22	Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich Tumor. <i>Cancer Research</i> , 2016, 76, 6266-6277.	0.4	74
23	WOMEN IN CANCER THEMATIC REVIEW: Systemic therapies in neuroendocrine tumors and novel approaches toward personalized medicine. <i>Endocrine-Related Cancer</i> , 2016, 23, T135-T154.	1.6	17
25	Fulminant Myocarditis with Combination Immune Checkpoint Blockade. <i>New England Journal of Medicine</i> , 2016, 375, 1749-1755.	13.9	1,668
26	Embracing a Standard of Care for Merkel Cell Carcinoma With Immunotherapy. <i>Clinical Skin Cancer</i> , 2016, 1, 53-56.	0.1	0
27	Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. , 2016, 4, 70.		132
28	Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities. <i>RMD Open</i> , 2016, 2, e000321.	1.8	37
29	Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma. <i>Journal of Hematology and Oncology</i> , 2016, 9, 48.	6.9	28
30	Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival. <i>Cancer Immunology Research</i> , 2017, 5, 137-147.	1.6	73
31	<sc>PD</sc> checkpoint blockade is an emerging treatment for Merkel cell carcinoma. <i>British Journal of Dermatology</i> , 2017, 176, 18-18.	1.4	2
32	Durable response to programmed death-1 (PD-1) blockade in a metastatic gastric cancer patient with mismatch repair deficiency and microsatellite instability. <i>Journal of Cancer Research and Practice</i> , 2017, 4, 72-75.	0.2	1
33	PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma. <i>Oncology</i> , 2017, 6, e1279777.	2.1	50
34	Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2017, 35, 1341-1367.	0.8	318
35	Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis. <i>Cancer Treatment Reviews</i> , 2017, 54, 34-42.	3.4	46
36	Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. <i>Cancer Immunology Research</i> , 2017, 5, 106-117.	1.6	236
37	Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 105, 17-22.	0.9	48
38	Factors influencing radiation treatment recommendations in early-stage Merkel cell carcinoma: a survey of US-based radiation oncologists. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 281-287.	1.1	8

#	ARTICLE	IF	CITATIONS
39	Medication-associated gastrointestinal tract injury. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 245-266.	1.4	22
40	Cardiovascular Toxicities Associated with Cancer Immunotherapies. <i>Current Cardiology Reports</i> , 2017, 19, 21.	1.3	126
42	Immunoprofiling as a predictor of patientâ€™s response to cancer therapyâ€™ promises and challenges. <i>Current Opinion in Immunology</i> , 2017, 45, 60-72.	2.4	39
43	Targeting neoantigens to augment antitumour immunity. <i>Nature Reviews Cancer</i> , 2017, 17, 209-222.	12.8	724
45	PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis. <i>Scientific Reports</i> , 2017, 7, 44173.	1.6	70
46	Reduced H3K27me3 expression in Merkel cell polyoma virus-positive tumors. <i>Modern Pathology</i> , 2017, 30, 877-883.	2.9	34
47	Immune checkpoint inhibitors in challenging populations. <i>Cancer</i> , 2017, 123, 1904-1911.	2.0	266
48	Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. <i>Cancer Immunology Research</i> , 2017, 5, 312-318.	1.6	354
49	Let This Be Our New Year's Pledge. <i>Oncologist</i> , 2017, 22, 1-2.	1.9	42
50	Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers. <i>Digestion</i> , 2017, 95, 109-114.	1.2	59
51	Designing nanomedicine for immuno-oncology. <i>Nature Biomedical Engineering</i> , 2017, 1, .	11.6	178
52	Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment Modalities. <i>JAMA Dermatology</i> , 2017, 153, 285.	2.0	39
53	Ipilimumab has efficacy in metastatic Merkel cell carcinoma: a case series of five patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e389-e391.	1.3	21
54	'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. <i>Nature Immunology</i> , 2017, 18, 255-262.	7.0	361
55	Unraveling molecular pathways of poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: A systematic review. <i>Cancer Treatment Reviews</i> , 2017, 56, 28-35.	3.4	57
56	Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade: A Key Player Against Various Cancers. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 851-861.	1.2	82
57	Malignant pheochromocytomaâ€™ paraganglioma: pathogenesis, TNM staging, and current clinical trials. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2017, 24, 174-183.	1.2	70
58	Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1113-1121.	2.0	29

#	ARTICLE	IF	CITATIONS
59	Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy. <i>Nature Nanotechnology</i> , 2017, 12, 763-769.	15.6	136
60	Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study. <i>Annals of Oncology</i> , 2017, 28, 1996-2001.	0.6	223
61	Whither Radioimmunotherapy: To Be or Not To Be?. <i>Cancer Research</i> , 2017, 77, 2191-2196.	0.4	60
62	New developments in the biology and the treatment of metastatic Merkel cell carcinoma. <i>Current Opinion in Oncology</i> , 2017, 29, 221-226.	1.1	42
63	Tumor-Infiltrating Lymphocyte Therapy and Neoantigens. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 138-143.	1.0	30
64	Polyomavirus-Negative Merkel Cell Carcinoma: A More Aggressive Subtype Based on Analysis of 282 Cases Using Multimodal Tumor Virus Detection. <i>Journal of Investigative Dermatology</i> , 2017, 137, 819-827.	0.3	203
65	Primary Resistance to PD-1 Blockade Mediated by <i>JAK1/2</i> Mutations. <i>Cancer Discovery</i> , 2017, 7, 188-201.	7.7	997
66	Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1977-1984.	1.2	14
67	PD-L1 Expression in Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw304.	3.0	43
68	Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: AARENAPE study. <i>European Journal of Surgical Oncology</i> , 2017, 43, 1915-1923.	0.5	23
69	Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2770-2780.	1.8	210
70	Biology, evolution, and medical importance of polyomaviruses: An update. <i>Infection, Genetics and Evolution</i> , 2017, 54, 18-38.	1.0	112
71	Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma. <i>Scientific Reports</i> , 2017, 7, 2290.	1.6	99
72	PD-1 and PD-L1 in neoplastic cells and the tumor microenvironment of Merkel cell carcinoma. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 740-746.	0.7	32
73	Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management. <i>Targeted Oncology</i> , 2017, 12, 301-308.	1.7	66
74	Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade. , 2017, 5, 23.		118
75	Talimogene laherparepvec for regionally advanced Merkel cell carcinoma: A report of 2 cases. <i>JAAD Case Reports</i> , 2017, 3, 185-189.	0.4	31
76	Immune-related neurological toxicities among solid tumor patients treated with immune checkpoint inhibitors: a systematic review. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 725-736.	1.4	22

#	ARTICLE	IF	CITATIONS
77	Skin Cancers in Organ Transplant Recipients. American Journal of Transplantation, 2017, 17, 2509-2530.	2.6	151
78	Activation of Protein Kinase C β in Merkel Cell Polyomavirus-Induced Merkel Cell Carcinoma. JAMA Dermatology, 2017, 153, 931.	2.0	3
79	Age and Gender Associations of Virus Positivity in Merkel Cell Carcinoma Characterized Using a Novel RNA <i>In Situ</i> Hybridization Assay. Clinical Cancer Research, 2017, 23, 5622-5630.	3.2	31
80	Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. Annals of Oncology, 2017, 28, 1988-1995.	0.6	326
81	Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA. Future Oncology, 2017, 13, 1699-1710.	1.1	98
82	Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab. European Journal of Cancer, 2017, 77, 84-87.	1.3	42
83	Pancreatic Cancer: "A Riddle Wrapped in a Mystery inside an Enigma". Clinical Cancer Research, 2017, 23, 1629-1637.	3.2	38
84	Diagnosis and Treatment of Kaposi Sarcoma. American Journal of Clinical Dermatology, 2017, 18, 529-539.	3.3	98
85	Mechanistic and pharmacologic insights on immune checkpoint inhibitors. Pharmacological Research, 2017, 120, 1-9.	3.1	46
86	Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma. JAMA Oncology, 2017, 3, 974.	3.4	65
87	Cancer immunotherapies targeting the PD-1 signaling pathway. Journal of Biomedical Science, 2017, 24, 26.	2.6	501
88	The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 67-77.	3.3	112
89	Seeking Standards for the Detection of Merkel Cell Polyomavirus and its Clinical Significance. Journal of Investigative Dermatology, 2017, 137, 797-799.	0.3	12
90	Biomedical Research as a Team Sport. Journal of Investigative Dermatology, 2017, 137, 783-786.	0.3	0
91	Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma. Future Oncology, 2017, 13, 1263-1279.	1.1	113
92	Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. , 2017, 178, 31-47.		89
93	Radiation and Immune Checkpoint Blockade: From Bench to Clinic. Seminars in Radiation Oncology, 2017, 27, 289-298.	1.0	39
94	Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study. Cancer, 2017, 123, 1464-1474.	2.0	132

#	ARTICLE	IF	CITATIONS
95	Molecular approaches for classifying endometrial carcinoma. <i>Gynecologic Oncology</i> , 2017, 145, 200-207.	0.6	137
96	Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. <i>European Journal of Cancer</i> , 2017, 71, 53-69.	1.3	307
97	Merkel cell carcinoma. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17077.	18.1	393
98	Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1493-1501.	5.1	921
99	Concurrent Merkel Cell Carcinoma and Melanoma in Individual Patients Presents a Treatment Challenge: A Case Series. <i>Clinical Skin Cancer</i> , 2017, 2, 69-72.	0.1	1
100	Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 119, 1-12.	2.0	141
101	Merkel Cell Polyomavirus: A New DNA Virus Associated with Human Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1018, 35-56.	0.8	9
102	Mechanisms regulating T-cell infiltration and activity in solid tumors. <i>Annals of Oncology</i> , 2017, 28, xii18-xii32.	0.6	276
103	Response of advanced stage recurrent lymphoepithelioma-like carcinoma to nivolumab. <i>Immunotherapy</i> , 2017, 9, 955-961.	1.0	34
104	Avelumab and other recent advances in Merkel cell carcinoma. <i>Future Oncology</i> , 2017, 13, 2771-2783.	1.1	11
105	Reply to "Recent advances in systemic targeted therapy for cutaneous T-cell lymphoma". <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1537-1537.	0.9	0
106	Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2598-2608.	1.9	1,779
107	Cutaneous infections from viral sources in solid organ transplant recipients. <i>Journal of Clinical Virology</i> , 2017, 97, 33-37.	1.6	11
108	Microbiota dysbiosis in select human cancers: Evidence of association and causality. <i>Seminars in Immunology</i> , 2017, 32, 25-34.	2.7	138
109	Efficacy of isolated limb perfusion (ILP) in patients with Merkel cell carcinoma (MCC): A multicenter experience. <i>European Journal of Surgical Oncology</i> , 2017, 43, 2157-2162.	0.5	12
110	Advances in Merkel cell carcinoma from a pathologist's perspective. <i>Pathology</i> , 2017, 49, 568-574.	0.3	16
111	Trial watch: Immune checkpoint blockers for cancer therapy. <i>Onc Immunology</i> , 2017, 6, e1373237.	2.1	62
112	Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies. <i>Clinical Cancer Research</i> , 2017, 23, 4950-4958.	3.2	46

#	ARTICLE	IF	CITATIONS
113	Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 517-532.	2.6	41
114	T cell therapies for human polyomavirus diseases. <i>Cytotherapy</i> , 2017, 19, 1302-1316.	0.3	17
115	Merkel cell polyomavirus and Merkel cell carcinoma. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2017, 372, 20160276.	1.8	78
116	Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma. <i>Immunotherapy</i> , 2017, 9, 797-804.	1.0	30
117	Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma. <i>Oncolmmunology</i> , 2017, 6, e1338237.	2.1	47
118	The Challenge for Development of Valuable Immuno-oncology Biomarkers. <i>Clinical Cancer Research</i> , 2017, 23, 4970-4979.	3.2	76
119	Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review. <i>Cancer Treatment Reviews</i> , 2017, 59, 71-78.	3.4	88
120	Cancer Immunotherapies: Are They as Effective in the Elderly?. <i>Drugs and Aging</i> , 2017, 34, 567-581.	1.3	31
121	Merkel Cell Carcinoma of the Head and Neck: Recommendations for Diagnostics and Treatment. <i>Annals of Surgical Oncology</i> , 2017, 24, 3430-3437.	0.7	24
122	Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw277.	3.0	28
123	Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. <i>Nature</i> , 2017, 549, 106-110.	13.7	501
124	Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade. <i>Cancer Cell</i> , 2017, 32, 253-267.e5.	7.7	430
125	Complications rhumatologiques de l'immunothérapie anticancéreuse. <i>Revue Du Rhumatisme (Edition) Tj</i> 0,6	0,6	0
126	Checkpoint inhibition in pediatric hematologic malignancies. <i>Pediatric Hematology and Oncology</i> , 2017, 34, 379-394.	0.3	23
127	PD-L1 blockade with avelumab: A new paradigm for treating Merkel cell carcinoma. <i>Cancer Biology and Therapy</i> , 2017, 18, 937-939.	1.5	17
128	De-novo and acquired resistance to immune checkpoint targeting. <i>Lancet Oncology, The</i> , 2017, 18, e731-e741.	5.1	568
129	Infectious Agents Associated Cancers: Epidemiology and Molecular Biology. <i>Advances in Experimental Medicine and Biology</i> , 2017, , .	0.8	4
130	Cardiotoxicity of immune checkpoint inhibitors. <i>ESMO Open</i> , 2017, 2, e000247.	2.0	186

#	ARTICLE	IF	CITATIONS
131	Brachial Plexus Neuritis Associated With Anti-Programmed Cell Death-1 Antibodies: Report of 2 Cases. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2017, 1, 192-197.	1.2	22
133	Immune Checkpoint Inhibition in Cancers that Affect the Head and Neck. International Journal of Radiation Oncology Biology Physics, 2017, 98, 969-973.	0.4	3
134	Combination Therapy with NHS-muLL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models. Clinical Cancer Research, 2017, 23, 5869-5880.	3.2	52
135	Update on Merkel Cell Carcinoma. Clinics in Laboratory Medicine, 2017, 37, 485-501.	0.7	67
136	Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report. Gynecologic Oncology Research and Practice, 2017, 4, 3.	3.6	64
137	The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives. Immunotherapy, 2017, 9, 647-657.	1.0	19
138	Harnessing the Immune System as a Therapeutic Tool in Virus-Associated Cancers. JAMA Oncology, 2017, 3, 106.	3.4	16
139	Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors?. Human Vaccines and Immunotherapeutics, 2017, 13, 528-532.	1.4	30
140	Immune-Related Adverse Effects of Cancer Immunotherapy Implications for Rheumatology. Rheumatic Disease Clinics of North America, 2017, 43, 65-78.	0.8	101
141	Tumor Mutational Burden and Response Rate to PD-1 Inhibition. New England Journal of Medicine, 2017, 377, 2500-2501.	13.9	2,321
142	Biology and evolution of poorly differentiated neuroendocrine tumors. Nature Medicine, 2017, 23, 664-673.	15.2	192
143	MCVdb: A database for knowledge discovery in Merkel cell polyomavirus with applications in T cell immunology and vaccinology. , 2017, , .		1
145	Immune Checkpoint in Glioblastoma: Promising and Challenging. Frontiers in Pharmacology, 2017, 8, 242.	1.6	133
146	Viral Oncology: Molecular Biology and Pathogenesis. Journal of Clinical Medicine, 2017, 6, 111.	1.0	118
147	A Century of Radiation Therapy and Adaptive Immunity. Frontiers in Immunology, 2017, 8, 431.	2.2	47
148	Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel. Frontiers in Immunology, 2017, 8, 267.	2.2	61
149	PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells. Frontiers in Immunology, 2017, 8, 572.	2.2	59
150	The Feasibility and Safety of Surgery in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Study. Frontiers in Oncology, 2017, 7, 121.	1.3	48

#	ARTICLE	IF	CITATIONS
151	Immunotherapy Combined with Large Fractions of Radiotherapy: Stereotactic Radiosurgery for Brain Metastases—Implications for Intraoperative Radiotherapy after Resection. <i>Frontiers in Oncology</i> , 2017, 7, 147.	1.3	24
152	Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms. <i>BioMed Research International</i> , 2017, 2017, 1-12.	0.9	25
153	Is this the end of cytotoxic chemotherapy in Merkel cell carcinoma?. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4803-4807.	1.0	14
154	Coincident Metastatic Melanoma and Merkel Cell Carcinoma with Complete Remission on Treatment with Pembrolizumab. <i>Acta Dermato-Venereologica</i> , 2017, 97, 1252-1254.	0.6	3
155	Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. <i>Oncolmmunology</i> , 2017, 6, e1344805.	2.1	142
156	Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2017, 10, 174.	6.9	92
157	Sentinel lymph node biopsy in periocular merkel cell carcinoma: a case report. <i>BMC Research Notes</i> , 2017, 10, 490.	0.6	4
159	The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?. <i>Cancer Biology and Medicine</i> , 2017, 14, 341.	1.4	4
160	Sustained Oligoclonal T Cell Expansion Correlates with Durable Response to Immune Checkpoint Blockade in Lung Cancer. <i>Journal of Cancer Science & Therapy</i> , 2017, 9, .	1.7	5
161	Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2851-2860.	2.0	34
162	Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients. <i>Cancer Management and Research</i> , 2018, Volume 10, 1-11.	0.9	23
163	The non-T-cell-inflamed tumor microenvironment: contributing factors and therapeutic solutions. <i>Emerging Topics in Life Sciences</i> , 2017, 1, 447-456.	1.1	2
164	Antitumor and Anti-“Hepatitis C Viral Response After Administration of the Anti-“Programmed Death 1 Antibody Pembrolizumab. <i>Journal of Oncology Practice</i> , 2017, 13, 462-464.	2.5	8
165	Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 4050-4056.	0.8	335
166	Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors. <i>JCO Precision Oncology</i> , 2017, 2017, 1-13.	1.5	44
167	Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 641-650.	1.8	9
168	Implementing liquid biopsies into clinical decision making for cancer immunotherapy. <i>Oncotarget</i> , 2017, 8, 48507-48520.	0.8	63
169	Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis. <i>JCO Precision Oncology</i> , 2017, 1, 1-15.	1.5	57

#	ARTICLE	IF	CITATIONS
170	Biopsy-Proven Metastatic Merkel Cell Carcinoma to the Orbit: Case Report and Review of Literature. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2018, 34, e86-e88.	0.4	8
171	Engineering chimeric antigen receptor-T cells for cancer treatment. <i>Molecular Cancer</i> , 2018, 17, 32.	7.9	57
172	Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1 ⁺ Tim-3 ⁺ CD8 ⁺ T Cells. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	14
173	PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 345-359.	1.3	27
174	Avelumab: a new standard for treating metastatic Merkel cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 319-326.	1.1	23
175	Cabozantinib in Patients with Advanced Merkel Cell Carcinoma. <i>Oncologist</i> , 2018, 23, 814-821.	1.9	30
176	Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus. <i>Clinical Cancer Research</i> , 2018, 24, 3644-3655.	3.2	18
177	Sequentially Responsive Therapeutic Peptide Assembling Nanoparticles for Dual-Targeted Cancer Immunotherapy. <i>Nano Letters</i> , 2018, 18, 3250-3258.	4.5	255
178	Checkpoint-Inhibitor nun auch zur Therapie des metastasierten Merkelzellkarzinoms zugelassen. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 394-395.	0.4	1
179	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 1976-1986.	13.9	1,495
180	Immune Checkpoint Inhibitors: Game Changing Cancer Therapy With a Cardiac Cost. What Are the Mechanisms and Unresolved Questions in Cardiotoxicity?. <i>Canadian Journal of Cardiology</i> , 2018, 34, 970-971.	0.8	1
181	Skin Diseases in the Immunosuppressed. , 2018, , .		2
182	Avelumab: A Review of Its Application in Metastatic Merkel Cell Carcinoma. <i>Annals of Pharmacotherapy</i> , 2018, 52, 928-935.	0.9	10
183	Poly ADP-ribose polymerase-1 as a potential therapeutic target in Merkel cell carcinoma. <i>Head and Neck</i> , 2018, 40, 1676-1684.	0.9	9
184	Cutaneous Malignancies in Solid Organ Transplant Recipients. , 2018, , 91-116.		0
185	Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 89-105.	1.1	13
187	Targeting cancer stem cells in the clinic: Current status and perspectives. , 2018, 187, 13-30.		61
188	CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. <i>Annual Review of Medicine</i> , 2018, 69, 301-318.	5.0	432

#	ARTICLE	IF	CITATIONS
189	A novel role for coinhibitory receptors/checkpoint proteins in the immunopathology of sepsis. <i>Journal of Leukocyte Biology</i> , 2018, 103, 1151-1164.	1.5	25
190	Prospective analysis of the utility of 18â€œFDG PETâ€œ in Merkel cell carcinoma of the skin: A Trans Tasman Radiation Oncology Group Study, <sc>TROG</sc> 09:03. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2018, 62, 412-419.	0.9	31
191	Reprint of: Virus-Specific T Cells: Broadening Applicability. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S1-S6.	2.0	7
195	Hypermutated Tumors and Immune Checkpoint Inhibition. <i>Drugs</i> , 2018, 78, 155-162.	4.9	22
196	M7824, a novel bifunctional anti-PD-L1/TGFÎ² Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine. <i>Oncolmmunology</i> , 2018, 7, e1426519.	2.1	162
197	Mechanisms of Resistance to PD-1 and PD-L1 Blockade. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 47-53.	1.0	287
198	Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade. <i>Journal of the National Cancer Institute</i> , 2018, 110, 787-790.	3.0	123
199	Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 457-463.e2.	0.6	346
200	Merkel cell carcinoma: An update and review. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 445-454.	0.6	90
201	Sentinel lymph node biopsy in Merkel cell carcinoma: The Mayo Clinic experience of 150 patients. <i>Surgical Oncology</i> , 2018, 27, 11-17.	0.8	48
202	Potential cardiac risk of immuneâ€œcheckpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects. <i>Medicinal Research Reviews</i> , 2018, 38, 1447-1468.	5.0	27
203	Surgical damage to the lymphatic system promotes tumor growth via impaired adaptive immune response. <i>Journal of Dermatological Science</i> , 2018, 90, 46-51.	1.0	9
204	PD-L1 and Other Immunological Diagnosis Tools. , 2018, , 371-385.		2
205	Merkel Cell Carcinoma Patients Presenting Without a Primary Lesion Have Elevated Markers of Immunity, Higher Tumor Mutation Burden, and Improved Survival. <i>Clinical Cancer Research</i> , 2018, 24, 963-971.	3.2	57
206	Improving immuneâ€œvascular crosstalk for cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2018, 18, 195-203.	10.6	340
207	PD-1 blockade with nivolumab in endemic Kaposi sarcoma. <i>Annals of Oncology</i> , 2018, 29, 1067-1069.	0.6	34
208	Adjuvant radiation therapy improves patient survival in earlyâ€œstage merkel cell carcinoma: A 15â€œyear singleâ€œinstitution study. <i>Laryngoscope</i> , 2018, 128, 1862-1866.	1.1	15
209	A Believerâ€œs Overview of Cancer Immunosurveillance and Immunotherapy. <i>Journal of Immunology</i> , 2018, 200, 385-391.	0.4	103

#	ARTICLE	IF	CITATIONS
210	High response rate to PD-1 blockade in desmoplastic melanomas. <i>Nature</i> , 2018, 553, 347-350.	13.7	269
211	Are there multiple cells of origin of Merkel cell carcinoma?. <i>Oncogene</i> , 2018, 37, 1409-1416.	2.6	84
212	The Case for a Primary Surgical Approach. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 15-16.	0.4	0
213	Novel Technology to Assess Programmed Death-Ligand 1 Expression by Multiplex Immunofluorescence and Image Analysis. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, e22-e24.	0.6	9
214	The Basics of Cancer Immunotherapy. , 2018, , .		5
215	Immunotherapy for Other Malignancies. , 2018, , 125-142.		0
216	Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences. <i>Targeted Oncology</i> , 2018, 13, 125-140.	1.7	19
217	Immunotherapy for Merkel cell carcinoma: a turning point in patient care. , 2018, 6, 23.		34
218	Treatment resistance in urothelial carcinoma: an evolutionary perspective. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 495-509.	12.5	37
219	A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure. <i>Clinical Cancer Research</i> , 2018, 24, 3519-3527.	3.2	80
220	<sc>CK</sc> 20â€positive and <sc>CK</sc> 7â€negative Merkel cell carcinoma of the cheek. <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 549-550.	0.2	0
221	CHECKPOINT INHIBITOR IMMUNE THERAPY. <i>Retina</i> , 2018, 38, 1063-1078.	1.0	252
222	Correlates of immune and clinical activity of novel cancer vaccines. <i>Seminars in Immunology</i> , 2018, 39, 119-136.	2.7	54
223	Liquid Biopsies and Cancer Immunotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 78-83.	1.0	18
224	Factors associated with advanced-stage Merkel cell carcinoma at initial diagnosis and the use of radiation therapy: Results from the National Cancer Database. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 680-688.	0.6	9
225	Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 1816-1823.	3.2	190
226	Update on Merkel Cell Carcinoma. <i>Head and Neck Pathology</i> , 2018, 12, 31-43.	1.3	30
228	Surgical resection improves median overall survival with marginal improvement in long-term survival when compared with definitive radiotherapy in Merkel cell carcinoma: A propensity score matched analysis of the National Cancer Database. <i>American Journal of Surgery</i> , 2018, 215, 384-387.	0.9	34

#	ARTICLE	IF	CITATIONS
229	Cancer immunotherapy using checkpoint blockade. <i>Science</i> , 2018, 359, 1350-1355.	6.0	4,274
230	Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma. <i>JAMA Oncology</i> , 2018, 4, e180077.	3.4	304
231	Rapidly Growing Eyelid Mass in an Elderly Man. <i>JAMA Ophthalmology</i> , 2018, 136, 710.	1.4	0
232	Living with Merkel Cell Carcinoma (MCC): Development of a Conceptual Model of MCC Based on Patient Experiences. <i>Patient</i> , 2018, 11, 439-449.	1.1	9
233	Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens. <i>JAMA Oncology</i> , 2018, 4, 173.	3.4	753
234	Adverse glycaemic effects of cancer therapy: indications for a rational approach to cancer patients with diabetes. <i>Metabolism: Clinical and Experimental</i> , 2018, 78, 141-154.	1.5	47
235	Virus-Specific T Cells: Broadening Applicability. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 13-18.	2.0	37
236	Endocrinopathies with use of cancer immunotherapies. <i>Clinical Endocrinology</i> , 2018, 88, 327-332.	1.2	20
237	The application and mechanism of PD pathway blockade for cancer therapy. <i>Postgraduate Medical Journal</i> , 2018, 94, 53-60.	0.9	10
238	<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. <i>Cancer Discovery</i> , 2018, 8, 196-215.	7.7	392
239	Integrated functional and mass spectrometry-based flow cytometric phenotyping to describe the immune microenvironment in acute myeloid leukemia. <i>Journal of Immunological Methods</i> , 2018, 453, 44-52.	0.6	19
240	Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMECC. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 341-351.	2.0	88
241	Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes. <i>Clinical Cancer Research</i> , 2018, 24, 2035-2043.	3.2	75
242	Towards personalized, tumour-specific, therapeutic vaccines for cancer. <i>Nature Reviews Immunology</i> , 2018, 18, 168-182.	10.6	736
243	Mechanisms of Tumor Cell "Intrinsic Immune Evasion. <i>Annual Review of Cancer Biology</i> , 2018, 2, 213-228.	2.3	65
244	Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 55-70.	1.9	5
245	Implications of the tumor immune microenvironment for staging and therapeutics. <i>Modern Pathology</i> , 2018, 31, 214-234.	2.9	278
246	Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer. <i>Annual Review of Medicine</i> , 2018, 69, 333-347.	5.0	38

#	ARTICLE	IF	CITATIONS
247	Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment. <i>Journal of Immunology</i> , 2018, 200, 347-354.	0.4	181
248	Immune checkpoint inhibitors: new strategies to checkmate cancer. <i>Clinical and Experimental Immunology</i> , 2018, 191, 133-148.	1.1	57
249	Merkel cell carcinoma: Do Australians have a more aggressive variant and a worse outcome?. <i>Australasian Journal of Dermatology</i> , 2018, 59, 239-240.	0.4	3
250	Burden of Disease, Early Diagnosis, and Treatment of Merkel Cell Carcinoma in Latin America. <i>Journal of Global Oncology</i> , 2018, 4, 1-11.	0.5	5
251	Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. <i>Journal of Clinical Oncology</i> , 2018, 36, 633-641.	0.8	1,109
253	Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy. <i>Translational Lung Cancer Research</i> , 2018, 7, 647-660.	1.3	66
254	Immunotherapy in the Asiatic population: any differences from Caucasian population?. <i>Journal of Thoracic Disease</i> , 2018, 10, S1482-S1493.	0.6	42
255	Tumor mutational burden as predictive factor of response to immunotherapy. <i>Translational Lung Cancer Research</i> , 2018, 7, S358-S361.	1.3	8
256	A case report of recurrent Merkel cell carcinoma with synchronous metastases to the heart and stomach. <i>Medicine (United States)</i> , 2018, 97, e13032.	0.4	5
258	18F-FDG and 68Ga-somatostatin analogs PET/CT in patients with Merkel cell carcinoma: a comparison study. <i>EJNMMI Research</i> , 2018, 8, 64.	1.1	28
260	Aktuelle Therapiestudien beim Merkelzellkarzinom. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 1403-1404.	0.4	0
262	Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer. <i>Frontiers in Medicine</i> , 2018, 5, 351.	1.2	67
263	Letter to the Editor: Could Immunogenicity of Kaposi Sarcoma Be More Linked to Viral Antigens Than to the Tumor Mutational Burden?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1418-1419.	2.3	4
264	Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma. <i>JAAD Case Reports</i> , 2018, 4, 1004-1006.	0.4	16
265	Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine. <i>Genome Medicine</i> , 2018, 10, 93.	3.6	121
266	Neuroendocrine Key Regulator Gene Expression in Merkel Cell Carcinoma. <i>Neoplasia</i> , 2018, 20, 1227-1235.	2.3	16
267	Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy. , 2018, 6, 131.		35
268	Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer. <i>Chest</i> , 2018, 154, 1416-1423.	0.4	230

#	ARTICLE	IF	CITATIONS
269	Genomic Characterization of Six Virus-Associated Cancers Identifies Changes in the Tumor Immune Microenvironment and Altered Genetic Programs. <i>Cancer Research</i> , 2018, 78, 6413-6423.	0.4	33
270	Not All Immune Checkpoints Are Created Equal. <i>Frontiers in Immunology</i> , 2018, 9, 1909.	2.2	114
271	Immunotherapy for Merkel Cell Carcinoma. <i>Current Treatment Options in Oncology</i> , 2018, 19, 57.	1.3	12
272	The intracellular signalosome of PD-L1 in cancer cells. <i>Signal Transduction and Targeted Therapy</i> , 2018, 3, 26.	7.1	174
273	The application of nanotechnology in immune checkpoint blockade for cancer treatment. <i>Journal of Controlled Release</i> , 2018, 290, 28-45.	4.8	67
274	Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences. <i>Frontiers in Pharmacology</i> , 2018, 9, 1050.	1.6	48
275	The biology and treatment of Merkel cell carcinoma: current understanding and research priorities. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 763-776.	12.5	219
276	Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. , 2018, 6, 99.		129
277	Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. <i>Nature Communications</i> , 2018, 9, 3868.	5.8	211
279	A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma. <i>BMC Cancer</i> , 2018, 18, 1024.	1.1	3
280	Radiation Therapy in Merkel Cell Carcinoma. , 2018, , 1-20.		1
281	Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade. <i>Cancer Immunology Research</i> , 2018, 6, 1129-1135.	1.6	81
282	Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2018, 103, 7-16.	1.3	63
283	TIGIT: a novel immunotherapy target moving from bench to bedside. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1659-1667.	2.0	152
284	Immune-based therapeutic approaches to virus-associated cancers. <i>Current Opinion in Virology</i> , 2018, 32, 24-29.	2.6	4
285	Cellular sheddases are induced by Merkel cell polyomavirus small tumour antigen to mediate cell dissociation and invasiveness. <i>PLoS Pathogens</i> , 2018, 14, e1007276.	2.1	24
286	An integrated automated multispectral imaging technique that simultaneously detects and quantitates viral RNA and immune cell protein markers in fixed sections from Epstein-Barr virus-related tumours. <i>Annals of Diagnostic Pathology</i> , 2018, 37, 12-19.	0.6	20
287	Merkel Cell Carcinoma: Updates on Pathogenesis, Diagnosis, and Management. <i>Current Dermatology Reports</i> , 2018, 7, 158-168.	1.1	0

#	ARTICLE	IF	CITATIONS
289	Effect of Patient Immune Status on the Efficacy of Radiation Therapy and Recurrence-Free Survival Among 805 Patients With Merkel Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 330-339.	0.4	28
290	Merkel cell carcinoma and cellular cytotoxicity: sensitivity to cellular lysis and screening for potential target antigens suitable for antibody-dependent cellular cytotoxicity. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1209-1219.	2.0	9
291	Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician. <i>Journal of Pain and Symptom Management</i> , 2018, 56, 460-472.	0.6	14
292	Merkel cell carcinoma: Clinical outcome and prognostic factors in 351 patients. <i>Journal of Surgical Oncology</i> , 2018, 117, 1768-1775.	0.8	36
293	Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer. <i>Journal of Molecular Biology</i> , 2018, 430, 2014-2029.	2.0	42
294	Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough. <i>Oncologist</i> , 2018, 23, 1171-1177.	1.9	29
295	Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action. <i>Oncologist</i> , 2018, 23, 874-878.	1.9	89
296	Pembrolizumab-associated mucous membrane pemphigoid in a patient with Merkel cell carcinoma. <i>British Journal of Dermatology</i> , 2018, 179, 993-994.	1.4	36
297	Expression of CD3, PD-L1 and CTLA-4 in mammary and extra-mammary Paget disease. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1297-1303.	2.0	25
298	Systematic review of sentinel lymph node biopsy in Merkel cell carcinoma of the head and neck. <i>Head and Neck</i> , 2018, 40, 2704-2713.	0.9	25
299	Merkel Cell Carcinoma Masquerading As Cellulitis: A Case Report and Review of the Literature. <i>Current Oncology</i> , 2018, 25, 106-112.	0.9	1
300	Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 5873-5882.	3.2	45
301	Inhibition of GSK-3 β induces AP-1-mediated osteopontin expression to promote cholestatic liver fibrosis. <i>FASEB Journal</i> , 2018, 32, 4494-4503.	0.2	18
302	Radiotherapy for inoperable Merkel cell carcinoma: a systematic review and pooled analysis. <i>Dermatology Practical and Conceptual</i> , 2018, 8, 149-157.	0.5	13
303	High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma. <i>Oncolmmunology</i> , 2018, 7, e1475874.	2.1	20
304	In-field and abscopal response after short-course radiation therapy in patients with metastatic Merkel cell carcinoma progressing on PD-1 checkpoint blockade: a case series. , 2018, 6, 43.		37
305	Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma. , 2018, 6, 58.		48
306	Predictors of survival in neurometastatic Merkel cell carcinoma. <i>European Journal of Cancer</i> , 2018, 101, 152-159.	1.3	10

#	ARTICLE	IF	CITATIONS
307	Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches. Targeted Oncology, 2018, 13, 567-582.	1.7	12
308	Merkel Cell Carcinoma: An Update and Immunotherapy. Frontiers in Oncology, 2018, 8, 48.	1.3	40
309	Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. Frontiers in Oncology, 2018, 8, 86.	1.3	926
311	The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy?. International Journal of Molecular Sciences, 2018, 19, 747.	1.8	42
312	Role of Immunotherapy in the Treatment of Squamous Cell Carcinoma of the Anal Canal. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 903-908.	2.3	10
313	MicroRNAs as Potential Biomarkers in Merkel Cell Carcinoma. International Journal of Molecular Sciences, 2018, 19, 1873.	1.8	17
314	Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). , 2018, 6, 63.		344
316	Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma. Oncology Research and Treatment, 2018, 41, 391-394.	0.8	40
317	Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. Journal of Hematology and Oncology, 2018, 11, 15.	6.9	155
318	Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after 1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. , 2018, 6, 7.		263
319	Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia. Oncology Research and Treatment, 2018, 41, 306-312.	0.8	71
320	Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism. Endocrine Connections, 2018, 7, R196-R211.	0.8	10
321	CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas. EBioMedicine, 2018, 35, 233-243.	2.7	97
322	Molecular mechanisms of viral oncogenesis in humans. Nature Reviews Microbiology, 2018, 16, 684-698.	13.6	156
323	Immunotherapy in Merkel cell carcinoma: role of Avelumab. ImmunoTargets and Therapy, 2018, Volume 7, 15-19.	2.7	13
324	Evolving Paradigms in HIV Malignancies: Review of Ongoing Clinical Trials. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 1018-1026.	2.3	7
325	β Cell replacement. Current Opinion in Endocrinology, Diabetes and Obesity, 2018, 25, 251-257.	1.2	7
326	Management of Non-melanoma Skin Cancers: Rare Subtypes. , 2018, , 605-621.		0

#	ARTICLE	IF	CITATIONS
327	Management of Non-melanoma Skin Cancers: Merkel Cell Carcinoma. , 2018, , 623-636.		0
328	Primary Visceral Merkel Cell Carcinoma: A Case Report and Review of the Literature. American Journal of Dermatopathology, 2018, 40, 927-929.	0.3	3
329	Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 742-774.	2.3	202
330	Carcinoma neuroendocrino cutáneo primitivo. EMC - Dermatología, 2018, 52, 1-13.	0.1	0
331	Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue. Current Medicinal Chemistry, 2018, 25, 1327-1339.	1.2	99
332	Programmed death receptor Ligand 1 expression in eyelid sebaceous carcinoma: a consecutive case series of 41 patients. Acta Ophthalmologica, 2019, 97, e390-e396.	0.6	14
333	Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis. Nephrology Dialysis Transplantation, 2019, 34, 108-117.	0.4	137
334	Cyclophosphamide with or without fluorouracil followed by subcutaneous or intravenous interleukin-2 use in solid tumors: A feasibility off-label experience. Cytokine, 2019, 113, 50-60.	1.4	5
335	Acquired resistance to cancer immunotherapy. Seminars in Immunopathology, 2019, 41, 31-40.	2.8	34
336	Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma. Clinical Cancer Research, 2019, 25, 1185-1195.	3.2	97
337	Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors. Current Treatment Options in Oncology, 2019, 20, 74.	1.3	17
338	The role of Ki-67 in Asian triple negative breast cancers: a novel combinatory panel approach. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 709-725.	1.4	14
339	Evaluation of phospho-histone H3 in Asian triple-negative breast cancer using multiplex immunofluorescence. Breast Cancer Research and Treatment, 2019, 178, 295-305.	1.1	12
340	Immunotherapeutic approaches in nasopharyngeal carcinoma. Expert Opinion on Biological Therapy, 2019, 19, 1165-1172.	1.4	40
342	Cutaneous Scapular Lesion in an Elderly Woman. JAMA Oncology, 2019, 5, 1355.	3.4	2
343	Tumor Vasculatures: A New Target for Cancer Immunotherapy. Trends in Pharmacological Sciences, 2019, 40, 613-623.	4.0	79
344	Rapid onset type 1 diabetes associated with the programmed cell death-1 inhibitor pembrolizumab. Internal Medicine Journal, 2019, 49, 930-931.	0.5	5
345	The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer. Cancer Treatment Reviews, 2019, 78, 8-16.	3.4	47

#	ARTICLE	IF	CITATIONS
346	Complete response with neoadjuvant avelumab in Merkel cell carcinoma – A case report. <i>Oral Oncology</i> , 2019, 99, 104350.	0.8	6
347	Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series. , 2019, 7, 170.		36
348	Merkel cell carcinoma: a prompt diagnosis to increase survival. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e478-e480.	1.3	0
349	CTLA-4 antibody ipilimumab negatively affects CD4+ T-cell responses in vitro. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1359-1368.	2.0	23
350	Breaking avelumab resistance with combined ipilimumab and nivolumab in metastatic Merkel cell carcinoma?. <i>Annals of Oncology</i> , 2019, 30, 1667-1668.	0.6	10
351	T Cell Dysfunction in Cancer Immunity and Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 1719.	2.2	219
352	Updates on the Systemic Treatment of Advanced Non-melanoma Skin Cancer. <i>Frontiers in Medicine</i> , 2019, 6, 160.	1.2	27
353	The Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 369-386.	0.6	19
354	Treatment Patterns, Overall Survival, and Total Healthcare Costs of Advanced Merkel Cell Carcinoma in the USA. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 733-740.	1.0	7
355	First report on two cases of pleomorphic dermal sarcoma successfully treated with immune checkpoint inhibitors. <i>Oncolmunology</i> , 2019, 8, e1665977.	2.1	21
356	Relationship between Microsatellite Instability, Immune Cells Infiltration, and Expression of Immune Checkpoint Molecules in Ovarian Carcinoma: Immunotherapeutic Strategies for the Future. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5129.	1.8	19
357	Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. , 2019, 7, 267.		156
358	Correlations between microsatellite instability and the biological behaviour of tumours. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2891-2899.	1.2	89
359	Monoclonal Antibodies in Dermatooncology – State of the Art and Future Perspectives. <i>Cancers</i> , 2019, 11, 1420.	1.7	9
360	Merkel Cell Carcinoma – Current Controversies and Future Directions. <i>Clinical Oncology</i> , 2019, 31, 789-796.	0.6	15
361	Dual-Blockade Immune Checkpoint for Breast Cancer Treatment Based on a Tumor-Penetrating Peptide Assembling Nanoparticle. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 39513-39524.	4.0	54
362	Management of regional metastatic disease in cutaneous malignancy of the head and neck. 3. Merkel cell carcinoma. <i>British Journal of Oral and Maxillofacial Surgery</i> , 2019, 57, 847-856.	0.4	4
363	Imaging of Merkel Cell Carcinoma: What Imaging Experts Should Know. <i>Radiographics</i> , 2019, 39, 2069-2084.	1.4	21

#	ARTICLE	IF	CITATIONS
364	Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME)., 2019, 7, 294.		53
365	Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors. <i>Cancer Cell</i> , 2019, 36, 471-482.	7.7	280
366	Phagocytosis checkpoints as new targets for cancer immunotherapy. <i>Nature Reviews Cancer</i> , 2019, 19, 568-586.	12.8	557
367	Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. <i>Cell Research</i> , 2019, 29, 846-861.	5.7	160
368	C-reactive protein as an early marker of immune-related adverse events. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2625-2631.	1.2	59
369	Updates on Merkel Cell Carcinoma. <i>Dermatologic Clinics</i> , 2019, 37, 489-503.	1.0	23
370	Mapping the Binding Hot Spots on Human Programmed Cell Death 1 and Its Ligand with Free-Energy Simulations. <i>Journal of Chemical Information and Modeling</i> , 2019, 59, 4339-4349.	2.5	4
371	The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481986976.	1.4	31
372	Emerging Evidence for Infectious Causes of Cancer in the United States. <i>Epidemiologic Reviews</i> , 2019, 41, 82-96.	1.3	6
373	High-Grade Neuroendocrine Carcinoma of the Head and Neck: Human Papillomavirus Status and PD-L1 Expression. <i>Orl</i> , 2019, 81, 309-316.	0.6	4
374	Treatment and survival of Merkel cell carcinoma since 1993: A population-based cohort study in The Netherlands. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 977-983.	0.6	8
375	Management of Non-melanoma Skin Cancer in Transplant Recipients. <i>Clinical Oncology</i> , 2019, 31, 779-788.	0.6	27
376	Expression of CD38 on Macrophages Predicts Improved Prognosis in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2019, 10, 2093.	2.2	51
377	Comparison of survivor scores for differentiation therapy of cancer to those for checkpoint inhibition: Half full or half empty. <i>Tumor Biology</i> , 2019, 41, 101042831987374.	0.8	3
378	An update on diagnostic features of Merkel cell carcinoma. <i>Diagnostic Histopathology</i> , 2019, 25, 110-119.	0.2	0
379	Características clínico-epidemiológicas del carcinoma de células de Merkel en una serie de 38 pacientes. <i>Actas Dermo-sifiligráficas</i> , 2019, 110, 360-365.	0.2	6
382	<i>Pseudomonas</i> Exotoxin Immunotoxins and Anti-Tumor Immunity: From Observations at the Patient's Bedside to Evaluation in Preclinical Models. <i>Toxins</i> , 2019, 11, 20.	1.5	37
383	Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. <i>European Journal of Cancer</i> , 2019, 109, 21-27.	1.3	188

#	ARTICLE	IF	CITATIONS
384	Merkel cell carcinoma of the thigh: case report and review of the literature. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 535-540.	1.0	2
385	Epigenetic therapy in immune-oncology. <i>Nature Reviews Cancer</i> , 2019, 19, 151-161.	12.8	345
386	Pomalidomide increases immune surface marker expression and immune recognition of oncovirus-infected cells. <i>Oncoimmunology</i> , 2019, 8, e1546544.	2.1	23
387	Epidemiologic perspectives on immunosuppressed populations and the immunosurveillance and immunocontainment of cancer. <i>American Journal of Transplantation</i> , 2019, 19, 3223-3232.	2.6	31
388	Human oncoviruses: Mucocutaneous manifestations, pathogenesis, therapeutics, and prevention. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1-21.	0.6	33
389	Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?. <i>Annals of Oncology</i> , 2019, 30, 1448-1459.	0.6	146
390	Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study. <i>JAMA Oncology</i> , 2019, 5, 1332.	3.4	153
391	Immunosuppressive Tumor Microenvironment Status and Histological Grading of Endometrial Carcinoma. <i>Cancer Microenvironment</i> , 2019, 12, 169-179.	3.1	21
392	Application of PD-1 Blockade in Cancer Immunotherapy. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 661-674.	1.9	333
393	S2 Leitlinie Merkelzellkarzinom (MZK, MCC, neuroendokrines Karzinom der Haut) – Update 2018. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 562-577.	0.4	13
394	Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?. , 2019, 7, 141.		14
395	Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate. <i>Oncotarget</i> , 2019, 10, 17-29.	0.8	21
396	Polyomaviruses – be aware, be very aware. <i>British Journal of Dermatology</i> , 2019, 180, 1284-1284.	1.4	0
397	<p>Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 349-359.	0.7	4
398	Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunodeficiency virus and cancer. , 2019, 7, 130.		8
399	Molecular and immune targets for Merkel cell carcinoma therapy and prevention. <i>Molecular Carcinogenesis</i> , 2019, 58, 1602-1611.	1.3	5
400	Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade. <i>Pharmacological Research</i> , 2019, 145, 104258.	3.1	115
401	Immunotherapy in Nonmelanoma Skin Cancer. <i>Actas Dermo-sifiligráficas</i> , 2019, 110, 353-359.	0.2	1

#	ARTICLE	IF	CITATIONS
402	S2k guidelines for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) – update 2018. JDDG - Journal of the German Society of Dermatology, 2019, 17, 562-576.	0.4	27
403	Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 147-164.	1.8	459
404	MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series. Cancer Immunology, Immunotherapy, 2019, 68, 983-990.	2.0	62
405	PD-L1 Expression and Immune Cell Infiltration in Gastroenteropancreatic (GEP) and Non-GEP Neuroendocrine Neoplasms With High Proliferative Activity. Frontiers in Oncology, 2019, 9, 343.	1.3	47
406	Rescue of Immunotherapy-Refractory Metastatic Merkel Cell Carcinoma With Conventionally Fractionated Radiotherapy and Concurrent Pembrolizumab. Frontiers in Oncology, 2019, 9, 223.	1.3	21
407	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials. JAMA Oncology, 2019, 5, 1008.	3.4	526
408	Sentinel lymph node biopsy in clinically node-negative Merkel cell carcinoma: the Westmead Hospital experience. ANZ Journal of Surgery, 2019, 89, 520-523.	0.3	6
409	Clinical and Epidemiological Characteristics of Merkel Cell Carcinoma in a Series of 38 Patients. Actas Dermo-sifiligráficas, 2019, 110, 360-365.	0.2	0
410	A case of merkel leptomenigeal evolution after complete remission upon anti-PD-1 treatment. European Journal of Cancer, 2019, 113, 55-57.	1.3	2
411	Immune-phenotyping of pleomorphic dermal sarcomas suggests this entity as a potential candidate for immunotherapy. Cancer Immunology, Immunotherapy, 2019, 68, 973-982.	2.0	21
413	Manipulation of the Host Immune Response by Small DNA Tumor Viruses. Current Cancer Research, 2019, , 261-297.	0.2	1
414	Genomic correlates of response to immune checkpoint blockade. Nature Medicine, 2019, 25, 389-402.	15.2	346
416	Predictive markers in gastric cancer immunotherapy treatment – are we there yet?. Translational Gastroenterology and Hepatology, 2019, 4, 4-4.	1.5	2
417	Merkel cell carcinoma of the eyelid: A review. Survey of Ophthalmology, 2019, 64, 659-667.	1.7	29
418	Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy. Immunotherapy, 2019, 11, 515-529.	1.0	17
419	PD-1 Tumor Suppressor Signaling in T Cell Lymphomas. Trends in Immunology, 2019, 40, 403-414.	2.9	24
421	PD-1 (PDCD1) promoter methylation in Merkel cell carcinoma: prognostic relevance and relationship with clinico-pathological parameters. Modern Pathology, 2019, 32, 1359-1372.	2.9	19
422	Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. Journal of Clinical Oncology, 2019, 37, 693-702.	0.8	274

#	ARTICLE	IF	CITATIONS
423	Characterizing the Therapeutic Potential of a Potent BET Degradar in Merkel Cell Carcinoma. <i>Neoplasia</i> , 2019, 21, 322-330.	2.3	10
424	Pembrolizumab for Unresectable or Metastatic Melanoma in Patients Older than 85 Years of Age. <i>Dermatology</i> , 2019, 235, 219-224.	0.9	8
425	Prognostic value of CD8+PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer. , 2019, 7, 34.		75
426	Merkel Cell Polyoma Viral Load and Intratumoral CD8+ Lymphocyte Infiltration Predict Overall Survival in Patients With Merkel Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 20.	1.3	18
427	Association of Disease Recurrence With Survival Outcomes in Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck Treated With Multimodality Therapy. <i>JAMA Dermatology</i> , 2019, 155, 442.	2.0	27
428	New perspectives in Merkel cell carcinoma. <i>Current Opinion in Oncology</i> , 2019, 31, 72-83.	1.1	10
429	In-transit recurrence of Merkel cell carcinoma associated with Bowen's disease: The first reported case successfully treated by avelumab. <i>Journal of Dermatology</i> , 2019, 46, 440-443.	0.6	0
430	B7-H3 Expression in Merkel Cell Carcinoma-Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density. <i>Clinical Cancer Research</i> , 2019, 25, 3455-3467.	3.2	24
431	Merkel Cell Carcinoma: Therapeutic Update and Emerging Therapies. <i>Dermatology and Therapy</i> , 2019, 9, 209-222.	1.4	54
432	Integrating the Management of Nodal Metastasis Into the Treatment of Nonmelanoma Skin Cancer. <i>Seminars in Radiation Oncology</i> , 2019, 29, 171-179.	1.0	6
433	PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy. <i>Journal of Cellular Physiology</i> , 2019, 234, 16824-16837.	2.0	279
434	Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 391-407.	3.3	35
435	Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 87.	3.5	213
436	Immunotherapy and radiotherapy for metastatic cancers. <i>Annals of Palliative Medicine</i> , 2019, 8, 312-325.	0.5	33
437	The pioneers behind immune checkpoint blockers awarded the Nobel Prize in physiology or medicine 2018. <i>Acta Oncologica</i> , 2019, 58, 1-8.	0.8	14
438	Successful immunotherapy and irradiation in a HIV-positive patient with metastatic Merkel cell carcinoma. <i>Clinical and Translational Radiation Oncology</i> , 2019, 15, 42-45.	0.9	10
439	Immunotherapy for skin cancer. <i>International Immunology</i> , 2019, 31, 465-475.	1.8	47
440	Capital Efficiency for Development Stage Biotech-Based Firms: An IPO Perspective. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
441	Safety and Efficacy in Relapsed or Refractory Classic Hodgkinâ€™s Lymphoma Treated with PD-1 Inhibitors: A Meta-Analysis of 9 Prospective Clinical Trials. <i>BioMed Research International</i> , 2019, 2019, 1-13.	0.9	5
442	Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma. <i>Oncologist</i> , 2019, 24, 1375-1383.	1.9	22
443	Combined radio-immunotherapy leads to complete clinical regression of stage IV Merkel cell carcinoma. <i>BMJ Case Reports</i> , 2019, 12, e230518.	0.2	4
444	Caring for Patients Treated With Checkpoint Inhibitors for the Treatment of Metastatic Merkel Cell Carcinoma. <i>Seminars in Oncology Nursing</i> , 2019, 35, 150924.	0.7	1
445	Immune checkpoint inhibitors win the 2018 Nobel Prize. <i>Biomedical Journal</i> , 2019, 42, 299-306.	1.4	62
446	Heart Block Caused by Cardiac Metastasis From Merkel Cell Carcinoma: A Case Report. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2019, 3, 510-516.	1.2	2
447	Driving innovation for rare skin cancers: utilizing common tumours and machine learning to predict immune checkpoint inhibitor response. <i>Immuno-Oncology Technology</i> , 2019, 4, 1-7.	0.2	2
448	Cutaneous Disease in Kidney Transplantation Patients. , 2019, , 578-590.		1
450	PD-L1 Detectionâ€™ Pearls and Pitfalls Associated With Current Methodologies Focusing on Entities Relevant to Dermatopathology. <i>American Journal of Dermatopathology</i> , 2019, 41, 539-565.	0.3	8
451	Global PD-L1 Signals and Tumor-Infiltrating Lymphocytes: Markers of Immunogenicity in Different Subsets of Merkel Cell Carcinoma and Potential Therapeutic Implications. <i>American Journal of Dermatopathology</i> , 2019, 41, 819-825.	0.3	7
452	The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2019, 25, 5961-5971.	3.2	118
453	Human CD4+ T Cells Specific for Merkel Cell Polyomavirus Localize to Merkel Cell Carcinomas and Target a Required Oncogenic Domain. <i>Cancer Immunology Research</i> , 2019, 7, 1727-1739.	1.6	23
454	Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment. <i>Expert Review of Endocrinology and Metabolism</i> , 2019, 14, 381-398.	1.2	54
455	Differential Outcomes Among Immunosuppressed Patients With Merkel Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 82-88.	0.6	39
456	<p>Primary Pulmonary Lymphoepithelioma-Like Carcinoma Response Favorably To Nivolumab: A Case Report</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 8595-8600.	1.0	23
458	The Effect of Time to Postoperative Radiation Therapy on Survival in Resected Merkel Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 636-642.	0.6	8
459	Immune Checkpoints. , 2019, , 19-43.		0
460	Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3). <i>Neuroendocrinology</i> , 2019, 108, 54-62.	1.2	62

#	ARTICLE	IF	CITATIONS
461	Epidemiology of Merkel cell carcinoma. A population-based study from 1985 to 2013, in northeastern of France. <i>International Journal of Cancer</i> , 2019, 144, 741-745.	2.3	29
462	Completion Lymph Node Dissection or Radiation Therapy for Sentinel Node Metastasis in Merkel Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 386-394.	0.7	37
463	Effective effectors: How T cells access and infiltrate the central nervous system. , 2019, 197, 52-60.		11
464	Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 199-224.	3.3	53
465	Polyomaviruses of the skin: integrating molecular and clinical advances in an emerging class of viruses. <i>British Journal of Dermatology</i> , 2019, 180, 1302-1311.	1.4	21
466	Expression of Notch 3 and Jagged 1 Is Associated With Merkel Cell Polyomavirus Status and Prognosis in Merkel Cell Carcinoma. <i>Anticancer Research</i> , 2019, 39, 319-329.	0.5	10
467	Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. <i>Annals of Oncology</i> , 2019, 30, 44-56.	0.6	1,742
468	Immunotherapy in advanced gastric cancer, is it the future?. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 25-32.	2.0	97
469	Merkel Cell Carcinoma Review. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 39-52.	0.9	39
470	Novel Cancer Therapeutics in Geriatrics: What is Unique to the Aging Patient?. <i>Drugs and Aging</i> , 2019, 36, 1-11.	1.3	10
471	Product review: avelumab, an anti-PD-L1 antibody. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 891-908.	1.4	50
472	Cancer immunotherapy of patients with HIV infection. <i>Clinical and Translational Oncology</i> , 2019, 21, 713-720.	1.2	22
473	Heterogeneity of programmed death-ligand expression in a case of Merkel cell carcinoma exhibiting complete regression after multiple metastases. <i>British Journal of Dermatology</i> , 2019, 180, 1228-1229.	1.4	8
474	Anti-PD-1 in Merkel cell carcinoma and cutaneous squamous cell carcinoma, description of five cases and recent data from the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e159-e161.	1.3	4
475	Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma. <i>Annals of Oncology</i> , 2019, 30, 57-67.	0.6	167
476	Cancer immunotherapy: challenges and clinical applications. <i>Journal of Medical Genetics</i> , 2019, 56, 1-3.	1.5	22
477	Usefulness of ulceration and hyperkeratosis as clinical predictors of Merkel cell polyomavirus-negative and combined Merkel cell carcinoma: A retrospective study. <i>Journal of Dermatology</i> , 2019, 46, 103-109.	0.6	5
478	Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 463-474.	1.4	16

#	ARTICLE	IF	CITATIONS
479	Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 429-443.	1.2	13
480	Detection and Characterization of Circulating Tumor Cells in Patients with Merkel Cell Carcinoma. <i>Clinical Chemistry</i> , 2019, 65, 462-472.	1.5	24
481	Predictive Biomarkers and Targeted Therapies in the Skin. , 2019, , 463-474.		0
482	Merkel Cell Carcinoma in the HIV-1/AIDS Patient. <i>Cancer Treatment and Research</i> , 2019, 177, 211-229.	0.2	11
483	HIV/AIDS-Associated Viral Oncogenesis. <i>Cancer Treatment and Research</i> , 2019, , .	0.2	0
484	Management of Regional Lymph Nodes in Patients with Merkel Cell Carcinoma Following a Positive Sentinel Node Biopsy: Less May be More, But is Either Enough?. <i>Annals of Surgical Oncology</i> , 2019, 26, 315-317.	0.7	4
485	Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma. <i>Modern Pathology</i> , 2019, 32, 290-305.	2.9	45
486	Recurrent Merkel cell carcinoma of the gluteal region: A case report. <i>Dermatologic Therapy</i> , 2019, 32, e12749.	0.8	4
487	Expression of the IDO1/TDO2-AhR pathway in tumor cells or the tumor microenvironment is associated with Merkel cell polyomavirus status and prognosis in Merkel cell carcinoma. <i>Human Pathology</i> , 2019, 84, 52-61.	1.1	23
488	Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy. , 2019, 194, 84-106.		248
489	The Multiple Faces of Programmed Cell Death Ligand 1 Expression in Malignant and Nonmalignant Cells. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 287-294.	0.6	17
490	<i>Cancer Immunology</i> . , 2020, , 84-96.e5.		0
491	Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 440-459.	0.6	37
492	Cardiotoxicity associated with immune checkpoint inhibitors in cutaneous oncology. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 986-994.	0.6	2
493	Intraoperative Flurbiprofen Treatment Alters Immune Checkpoint Expression in Patients Undergoing Elective Thoracoscopic Resection of Lung Cancer. <i>Medical Principles and Practice</i> , 2020, 29, 150-159.	1.1	7
494	The Landmark Series: Non-melanoma Skin Cancers. <i>Annals of Surgical Oncology</i> , 2020, 27, 22-27.	0.7	13
495	Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 112-115.	1.4	47
496	Second Primary Cancers in Patients with Invasive and In Situ Squamous Cell Skin Carcinoma, Kaposi Sarcoma, and Merkel Cell Carcinoma: Role for Immune Mechanisms?. <i>Journal of Investigative Dermatology</i> , 2020, 140, 48-55.e1.	0.3	7

#	ARTICLE	IF	CITATIONS
497	Immune checkpoints in the tumor microenvironment. <i>Seminars in Cancer Biology</i> , 2020, 65, 1-12.	4.3	146
498	A multicenter analysis of genomic profiles and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the lung. <i>Modern Pathology</i> , 2020, 33, 626-638.	2.9	38
499	Danger is only skin deep: aggressive epidermal carcinomas. An overview of the diagnosis, demographics, molecular-genetics, staging, prognostic biomarkers, and therapeutic advances in Merkel cell carcinoma. <i>Modern Pathology</i> , 2020, 33, 42-55.	2.9	30
500	Development of therapeutic antibodies for the treatment of diseases. <i>Journal of Biomedical Science</i> , 2020, 27, 1.	2.6	1,277
501	Patterns of distant metastases in 215 Merkel cell carcinoma patients: Implications for prognosis and surveillance. <i>Cancer Medicine</i> , 2020, 9, 1374-1382.	1.3	52
502	Merkel cell carcinoma update: the case for two tumours. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1425-1431.	1.3	19
503	In situ multiplex immunofluorescence analysis of the inflammatory burden in kidney allograft rejection: A new tool to characterize the alloimmune response. <i>American Journal of Transplantation</i> , 2020, 20, 942-953.	2.6	36
504	Contemporary Topics in Radiation Medicine. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 189-203.	0.9	3
505	Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance. <i>Seminars in Cancer Biology</i> , 2020, 65, 114-122.	4.3	45
506	Nonmelanoma Skin Cancers. , 2020, , 1052-1073.e8.		1
507	Foci of Programmed Cell Death-Ligand 1 (PD-L1)-positive Tumor Areas With Tumor-infiltrating Leukocytes (TILs) Evocative of a PD-1/PD-L1-related Adaptive Immune Resistance are Frequent in Merkel Cell Carcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 17-22.	0.6	4
508	The immune checkpoints CTLA-4 and PD-L1 in carcinomas of the uterine cervix. <i>Pathology Research and Practice</i> , 2020, 216, 152782.	1.0	26
509	Prognostic Impact of MCPyV and TIL Subtyping in Merkel Cell Carcinoma: Evidence from a Large European Cohort of 95 Patients. <i>Endocrine Pathology</i> , 2020, 31, 21-32.	5.2	28
510	Large cell variant of Merkel cell carcinoma with clear cell change. <i>Journal of Cutaneous Pathology</i> , 2020, 47, 1-5.	0.7	4
511	Immune Checkpoint Inhibitors-Related Cardiotoxicity. <i>American Journal of Therapeutics</i> , 2020, 27, e591-e598.	0.5	14
512	The Programmed Death Pathway in Ocular Adnexal Sebaceous Carcinoma. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2020, 36, 74-79.	0.4	8
513	Biomarkers for Response to Immune Checkpoint Blockade. <i>Annual Review of Cancer Biology</i> , 2020, 4, 331-351.	2.3	29
514	Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. <i>Oncologist</i> , 2020, 25, e398-e404.	1.9	10

#	ARTICLE	IF	CITATIONS
516	Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity. <i>Theranostics</i> , 2020, 10, 1033-1045.	4.6	27
517	Development of Merkel Cell Carcinoma and Squamous Cell Carcinoma During Treatment With Pembrolizumab for Metastatic Mucosal Melanoma. <i>Dermatologic Surgery</i> , 2020, 46, 1443-1445.	0.4	1
518	Infiltrating pattern and prognostic value of tertiary lymphoid structures in resected non-functional pancreatic neuroendocrine tumors. , 2020, 8, e001188.		24
519	Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1. <i>Biomedicine and Pharmacotherapy</i> , 2020, 130, 110621.	2.5	8
520	Resolution of a High Grade and Metastatic BK Polyomavirus-Associated Urothelial Cell Carcinoma Following Radical Allograft Nephroureterectomy and Immune Checkpoint Treatment: A Case Report. <i>Transplantation Proceedings</i> , 2020, 52, 2720-2725.	0.3	6
521	Positron Emission Tomography in Merkel Cell Carcinoma. <i>Cancers</i> , 2020, 12, 2897.	1.7	9
522	CDK5 Inhibition Abrogates TNBC Stemâ€Cell Property and Enhances Antiâ€PDâ€1 Therapy. <i>Advanced Science</i> , 2020, 7, 2001417.	5.6	24
523	Nivolumab plus ipilimumab for soft tissue sarcoma: a single institution retrospective review. <i>Immunotherapy</i> , 2020, 12, 1303-1312.	1.0	11
524	Pembrolizumab and other immune checkpoint inhibitors in locally advanced or metastatic Merkel Cell Carcinoma: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 1093-1106.	1.1	4
525	Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients. <i>Melanoma Research</i> , 2020, 30, 364-375.	0.6	42
526	Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629). <i>Journal of Clinical Oncology</i> , 2020, 38, 2916-2925.	0.8	170
527	Merkel Cell Polyomavirus and Merkel Cell Carcinoma. <i>Cancers</i> , 2020, 12, 1774.	1.7	70
529	Case of Merkel cell carcinoma in a patient with pre-existing ILD. , 2020, 8, e001672.		1
530	PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy. , 2020, 8, e001631.		44
531	Non-Melanoma Skin Cancers: Biological and Clinical Features. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5394.	1.8	83
532	High Expression of Programmed Death Ligand 1 and Programmed Death Ligand 2 in Ophthalmic Sebaceous Carcinoma: The Case for a Clinical Trial of Checkpoint Inhibitors. <i>American Journal of Ophthalmology</i> , 2020, 220, 128-139.	1.7	8
533	The changing paradigm of managing Merkel cell carcinoma in Australia: An expert commentary. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 312-319.	0.7	13
534	Tailoring precision immunotherapy: coming to a clinic soon?. <i>ESMO Open</i> , 2020, 5, e000631.	2.0	8

#	ARTICLE	IF	CITATIONS
535	Modular design of Bi-specific nanoplatform engaged in malignant lymphoma immunotherapy. <i>Nanoscale</i> , 2020, 12, 18418-18428.	2.8	6
536	Tumor infiltrating lymphocyte grade in Merkel cell carcinoma: relationships with clinical factors and independent prognostic value. <i>Acta Oncologica</i> , 2020, 59, 1409-1415.	0.8	5
537	Retrospective Multicenter Analysis of the Outcome of a Re-Induction with Immune Checkpoint Inhibitors in Advanced Merkel Cell Carcinoma. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 2202-2207.	0.3	6
538	Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma. , 2020, 8, e000987.		70
539	Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments. <i>Current Treatment Options in Oncology</i> , 2020, 21, 86.	1.3	6
540	Spontaneous Regression and Complete Response to Immune Checkpoint Blockade in a Case of High-Grade Neuroendocrine Carcinoma. <i>JCO Precision Oncology</i> , 2020, 4, 1006-1011.	1.5	2
541	Real-world outcomes among US Merkel cell carcinoma patients initiating immune checkpoint inhibitors or chemotherapy. <i>Future Oncology</i> , 2020, 16, 2521-2536.	1.1	4
542	Postoperative, Single-Fraction Radiation Therapy in Merkel Cell Carcinoma of the Head and Neck. <i>Advances in Radiation Oncology</i> , 2020, 5, 1248-1254.	0.6	15
543	Merkel Cell Polyomavirus Small T Antigen Activates Noncanonical NF- κ B Signaling to Promote Tumorigenesis. <i>Molecular Cancer Research</i> , 2020, 18, 1623-1637.	1.5	18
544	An Aggressive Presentation of Merkel Cell Carcinoma: A Case Report. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2020, 8, 232470962096371.	0.3	1
545	The Tumor Microenvironment and Immunotherapy of Oropharyngeal Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 545385.	1.3	14
546	Robust Production of Merkel Cell Polyomavirus Oncogene Specific T Cells From Healthy Donors for Adoptive Transfer. <i>Frontiers in Immunology</i> , 2020, 11, 592721.	2.2	8
547	Bone Scintigraphy in Pembrolizumab-Induced Inflammatory Arthritis. <i>Clinical Nuclear Medicine</i> , 2020, 45, 999-1000.	0.7	2
548	Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy Responses. <i>Frontiers in Immunology</i> , 2020, 11, 587014.	2.2	56
549	Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative $\hat{\nu}$ exon 6 $\hat{\nu}$ TrkAll Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8222.	1.8	4
550	The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment. <i>Frontiers in Immunology</i> , 2020, 11, 568931.	2.2	100
551	Pancreatic Diseases and Microbiota: A Literature Review and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2020, 9, 3535.	1.0	10
553	Merkel Cell Carcinoma Treatment in Finland in 1986â€“2016â€“A Real-World Data Study. <i>Cancers</i> , 2020, 12, 1224.	1.7	5

#	ARTICLE	IF	CITATIONS
554	Scientifically based combination therapies with immuno-oncology checkpoint inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1711-1725.	1.1	6
555	Delta-Like Protein 3 Expression and Targeting in Merkel Cell Carcinoma. <i>Oncologist</i> , 2020, 25, 810-817.	1.9	11
556	Current Research in Melanoma and Aggressive Nonmelanoma Skin Cancer. <i>Facial Plastic Surgery</i> , 2020, 36, 200-210.	0.5	7
557	Management of primary skin cancer during a pandemic: Multidisciplinary recommendations. <i>Cancer</i> , 2020, 126, 3900-3906.	2.0	62
558	Selective reactivation of STING signaling to target Merkel cell carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 13730-13739.	3.3	39
559	Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts. <i>Scientific Reports</i> , 2020, 10, 8867.	1.6	13
561	Glioblastoma multiforme: novel therapeutic targets. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 605-614.	1.5	36
562	Reconstruction of cell spatial organization from single-cell RNA sequencing data based on ligand-receptor mediated self-assembly. <i>Cell Research</i> , 2020, 30, 763-778.	5.7	92
563	Circulating immune cell phenotype dynamics reflect the strength of tumor-immune cell interactions in patients during immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 16072-16082.	3.3	60
564	Well Differentiated Grade 3 Neuroendocrine Tumors of the Digestive Tract: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 1677.	1.0	23
565	Merkel Cell Carcinoma of the Head and Neck Compared to Other Anatomical Sites in a Real-World Setting: Importance of Surgical Therapy for Facial Tumors. <i>Facial Plastic Surgery</i> , 2020, 36, 249-254.	0.5	3
566	Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial. <i>Patient</i> , 2020, 13, 457-467.	1.1	11
567	Association of Programmed Death 1 Protein Ligand (PD-L1) Expression With Prognosis in Merkel Cell Carcinoma. <i>Frontiers in Medicine</i> , 2020, 7, 198.	1.2	4
568	Decreased survival and increased recurrence in Merkel cell carcinoma significantly linked with immunosuppression. <i>Journal of Surgical Oncology</i> , 2020, 122, 653-659.	0.8	10
569	Advances in quantitative immunohistochemistry and their contribution to breast cancer. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 509-522.	1.5	13
570	Clinical and molecular characterization of virus-positive and virus-negative Merkel cell carcinoma. <i>Genome Medicine</i> , 2020, 12, 30.	3.6	71
571	Histopathologic Characterization of Myocarditis Associated With Immune Checkpoint Inhibitor Therapy. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 1392-1396.	1.2	31
572	Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 421-430.	2.1	23

#	ARTICLE	IF	CITATIONS
573	Strong vaccine responses during chemotherapy are associated with prolonged cancer survival. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	83
574	Merkel cell carcinoma of an unknown primary. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 253-255.	0.4	1
575	Management Recommendations for Merkel Cell Carcinoma—A Danish Perspective. <i>Cancers</i> , 2020, 12, 554.	1.7	15
576	Development of an Immune Infiltration-Related Prognostic Scoring System Based on the Genomic Landscape Analysis of Glioblastoma Multiforme. <i>Frontiers in Oncology</i> , 2020, 10, 154.	1.3	20
577	Challenges of New Approaches in Metastatic Merkel Cell Carcinoma. <i>Case Reports in Oncology</i> , 2020, 13, 501-507.	0.3	6
578	Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma. <i>Current Treatment Options in Oncology</i> , 2020, 21, 62.	1.3	5
579	Uveitis secondary to cancer therapeutics. <i>Annals of Eye Science</i> , 2020, 5, 19-19.	1.1	2
580	Article Commentary: Cancer Immunotherapy for the General Surgeon. <i>American Surgeon</i> , 2020, 86, 284-292.	0.4	0
581	Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients. <i>Thoracic Cancer</i> , 2020, 11, 2406-2430.	0.8	40
582	Adverse events associated with immune checkpoint inhibitors: a new era in autoimmune diabetes. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2020, 27, 187-193.	1.2	7
583	Avelumab as an Emerging Therapy for Eyelid and Periocular Merkel Cell Carcinoma. <i>International Ophthalmology Clinics</i> , 2020, 60, 91-102.	0.3	6
584	Landscape of current and future therapies of Merkel cell carcinoma. <i>Dermatologic Therapy</i> , 2020, 33, e13281.	0.8	0
585	Combining DNA Damage Induction with BCL-2 Inhibition to Enhance Merkel Cell Carcinoma Cytotoxicity. <i>Biology</i> , 2020, 9, 35.	1.3	11
586	Immunobiology of Merkel cell carcinoma. <i>Current Opinion in Oncology</i> , 2020, 32, 114-121.	1.1	11
587	Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. <i>European Heart Journal</i> , 2020, 41, 1733-1743.	1.0	212
588	A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 1047-1060.	5.7	50
589	An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas. <i>Oncologist</i> , 2020, 25, e782-e788.	1.9	7
590	Trends in the incidence of Merkel cell carcinoma in Victoria, Australia, between 1986 and 2016. <i>Australasian Journal of Dermatology</i> , 2020, 61, e34-e38.	0.4	15

#	ARTICLE	IF	CITATIONS
591	Prognostic Biomarkers for Melanoma Immunotherapy. <i>Current Oncology Reports</i> , 2020, 22, 25.	1.8	13
592	Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma. <i>Cells</i> , 2020, 9, 263.	1.8	43
594	Molecular profiling for precision cancer therapies. <i>Genome Medicine</i> , 2020, 12, 8.	3.6	447
595	Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 2257-2267.	3.2	39
596	Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?. <i>International Journal of Cancer</i> , 2020, 146, 2305-2314.	2.3	44
597	Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC. <i>Journal of Clinical Pathology</i> , 2020, 73, 557-562.	1.0	53
598	Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination. <i>International Journal of Cancer</i> , 2020, 147, 1509-1518.	2.3	44
599	Neoadjuvant checkpoint blockade for cancer immunotherapy. <i>Science</i> , 2020, 367, .	6.0	553
600	<p>Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle<p>,. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 83-94.	1.0	27
601	Multimodality Cardiac Imaging in the Era of Emerging Cancer Therapies. <i>Journal of the American Heart Association</i> , 2020, 9, e013755.	1.6	37
602	An autoimmune-based, paraneoplastic neurologic syndrome following checkpoint inhibition and concurrent radiotherapy for merkel cell carcinoma: case report. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 664-670.	1.0	4
603	TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials. <i>Cancer Gene Therapy</i> , 2020, 27, 841-853.	2.2	94
604	A Therapeutic and Diagnostic Multidisciplinary Pathway for Merkel Cell Carcinoma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 529.	1.3	8
606	The safety and efficacy of immune checkpoint inhibitors in patients with advanced cancers and pre-existing chronic viral infections (Hepatitis B/C, HIV): A review of the available evidence. <i>Cancer Treatment Reviews</i> , 2020, 86, 102011.	3.4	31
607	Artesunate Affects T Antigen Expression and Survival of Virus-Positive Merkel Cell Carcinoma. <i>Cancers</i> , 2020, 12, 919.	1.7	17
608	Future Challenges in Cancer Resistance to Immunotherapy. <i>Cancers</i> , 2020, 12, 935.	1.7	41
609	Polyomavirusâ€driven Merkel cell carcinoma: Prospects for therapeutic vaccine development. <i>Molecular Carcinogenesis</i> , 2020, 59, 807-821.	1.3	32
610	A CT-based radiomics signature for evaluating tumor infiltrating Treg cells and outcome prediction of gastric cancer. <i>Annals of Translational Medicine</i> , 2020, 8, 469-469.	0.7	16

#	ARTICLE	IF	CITATIONS
611	Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy. <i>Cancer Communications</i> , 2020, 40, 135-153.	3.7	339
613	T-Cell Repertoire in Combination with T-Cell Density Predicts Clinical Outcomes in Patients with Merkel Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2146-2156.e4.	0.3	14
614	Pembrolizumab as first line treatment of Merkel cell carcinoma patients – a case series of patients with various co-morbidities. <i>Acta Oncologica</i> , 2020, 59, 793-796.	0.8	6
615	Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 598-607.	3.2	63
616	Merkel Cell Carcinoma: A 28-Year Experience. <i>Otolaryngology - Head and Neck Surgery</i> , 2020, 163, 364-371.	1.1	2
617	Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 2476-2487.	0.8	152
618	Prevalent and Diverse Intratumoral Oncoprotein-Specific CD8+ T Cells within Polyomavirus-Driven Merkel Cell Carcinomas. <i>Cancer Immunology Research</i> , 2020, 8, 648-659.	1.6	28
619	FDA Accelerated Approval of Pembrolizumab for Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma. <i>Oncologist</i> , 2020, 25, e1077-e1082.	1.9	21
620	Tumor Ulceration, Reduced Infiltration of CD8-Lymphocytes, High Neutrophil-to-CD8-Lymphocyte Ratio and Absence of MC Virus are Negative Prognostic Markers for Patients with Merkel Cell Carcinoma. <i>Cancers</i> , 2020, 12, 888.	1.7	8
621	Merkel cell polyomavirus activates LSD1-mediated blockade of non-canonical BAF to regulate transformation and tumorigenesis. <i>Nature Cell Biology</i> , 2020, 22, 603-615.	4.6	47
622	High somatostatin receptor expression and efficacy of somatostatin analogues in patients with metastatic Merkel cell carcinoma*. <i>British Journal of Dermatology</i> , 2021, 184, 319-327.	1.4	28
623	Primary Parotid Merkel Type Small Cell Neuroendocrine Carcinoma with Oligometastasis to the Brain and Adrenal Gland: Case Report and Review of Literature. <i>Head and Neck Pathology</i> , 2021, 15, 311-318.	1.3	5
624	The Clinical Utility of Neuron-Specific Enolase (NSE) Serum Levels as a Biomarker for Merkel Cell Carcinoma (MCC). <i>Annals of Surgical Oncology</i> , 2021, 28, 1019-1028.	0.7	20
625	Quantitative metastatic lymph node burden and survival in Merkel cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 312-320.	0.6	17
626	Biomarkers for predicting the outcome of various cancer immunotherapies. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103161.	2.0	10
627	Severe immune-related hepatitis induced by immune checkpoint inhibitors: Clinical features and management proposal. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101491.	0.7	18
628	Clinical benefit of baseline imaging in Merkel cell carcinoma: Analysis of 584 patients. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 330-339.	0.6	29
629	Myeloid-derived suppressor cells in gastroenteropancreatic neuroendocrine neoplasms. <i>Endocrine</i> , 2021, 71, 242-252.	1.1	5

#	ARTICLE	IF	CITATIONS
630	Carcinoma de c�lulas de Merkel: estudio descriptivo de 11 casos. Actas Dermo-sifilogr�ficas, 2021, 112, 63-68.	0.2	1
631	Clinical response to immune checkpoint inhibition in patients with advanced skin cancers receiving concurrent ruxolitinib therapy for haematological malignancy. British Journal of Dermatology, 2021, 184, 564-566.	1.4	1
632	Molecular Pathogenesis of Merkel Cell Carcinoma. Annual Review of Pathology: Mechanisms of Disease, 2021, 16, 69-91.	9.6	59
633	Exploring the knowledge gap of immune checkpoint inhibitors in chronic renal failure: A systematic review of the literature. Critical Reviews in Oncology/Hematology, 2021, 157, 103169.	2.0	14
634	The emerging role of immunotherapy for the treatment of sarcoma. Journal of Surgical Oncology, 2021, 123, 730-738.	0.8	16
635	PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1803-1811.	1.2	24
636	Tumor mutational burden as a tissue-agnostic biomarker for cancer immunotherapy. Expert Review of Clinical Pharmacology, 2021, 14, 141-143.	1.3	7
637	The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell, 2021, 39, 154-173.	7.7	491
638	Characterization of a single chain variable fragment of nivolumab that targets PD-1 and blocks PD-L1 binding. Protein Expression and Purification, 2021, 177, 105766.	0.6	7
639	Oncologic outcomes of patients with Merkel Cell Carcinoma (MCC): A multi-institutional cohort study. American Journal of Surgery, 2021, 221, 844-849.	0.9	5
640	Merkel cell carcinoma: A review. Journal of Cutaneous Pathology, 2021, 48, 411-421.	0.7	58
641	Reinvigorating exhausted CD8⁺ cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy. Medicinal Research Reviews, 2021, 41, 156-201.	5.0	56
642	T Cells Expanded from PD-1+ Peripheral Blood Lymphocytes Share More Clones with Paired Tumor-Infiltrating Lymphocytes. Cancer Research, 2021, 81, 2184-2194.	0.4	18
643	Molecules in Signal Pathways. , 2021, , 139-154.		0
644	Detection of Programmed Cell Death Ligand 1 Expression in Lung Cancer Clinical Samples by an Automated Immunohistochemistry System. Methods in Molecular Biology, 2021, 2279, 35-47.	0.4	1
646	Perspectives in immunotherapy: meeting report from the "ImmunoTherapy Bridge" (December 4th-5th), Tj ETQq1 1 0,784314	1.8	3
647	Deciphering the dual role and prognostic potential of PINK1 across cancer types. Neural Regeneration Research, 2021, 16, 659.	1.6	7
648	Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy. Frontiers in Immunology, 2020, 11, 563258.	2.2	24

#	ARTICLE	IF	CITATIONS
649	Review of Merkel cell carcinoma “ what is known and unknown. Oncolog-Hematolog Ro, 2021, 2, 20.	0.0	0
650	Avelumab. , 2021, , 313-325.		0
651	Immunotherapy in Immunosuppressed Patients. , 2021, , 429-440.		0
652	Merkel Cell Carcinoma: A Description of 11 Cases. Actas Dermo-sifilogrÃ¡ficas, 2021, 112, 63-68.	0.2	0
653	Emerging role of SWI/SNF complex deficiency as a target of immune checkpoint blockade in human cancers. Oncogenesis, 2021, 10, 3.	2.1	25
654	Miniature Fiber-Spectrophotometer for Real-Time Biomarkers Detection. IEEE Sensors Journal, 2021, 21, 14822-14837.	2.4	6
655	Emerging Viral Infections. Updates in Clinical Dermatology, 2021, , 91-110.	0.1	1
656	Response to PD-1 Immunotherapy in Metastatic Spiradenocarcinoma. JCO Precision Oncology, 2021, 5, 340-343.	1.5	1
657	Immunotherapy in Neuroendocrine Neoplasms: Where Are We Now?. Current Treatment Options in Oncology, 2021, 22, 19.	1.3	3
658	Stenotrophomonas-maltophilia inhibits host cellular immunity by activating PD-1/PD-L1 signaling pathway to induce T-cell exhaustion. Molecular Immunology, 2021, 130, 37-48.	1.0	3
659	Impact of cancer evolution on immune surveillance and checkpoint inhibitor response. Seminars in Cancer Biology, 2022, 84, 89-102.	4.3	21
660	Immune checkpoint inhibitor therapy in HIV-associated Merkel cell carcinoma: A case series of 3 patients. JAAD Case Reports, 2021, 8, 28-33.	0.4	3
661	Nanotechnology-based platforms to improve immune checkpoint blockade efficacy in cancer therapy. Future Oncology, 2021, 17, 711-722.	1.1	10
662	CD30+OX40+ Treg is associated with improved overall survival in colorectal cancer. Cancer Immunology, Immunotherapy, 2021, 70, 2353-2365.	2.0	13
663	Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduction and Targeted Therapy, 2021, 6, 72.	7.1	191
664	Improved survival in women versus men with merkel cell carcinoma. Journal of the American Academy of Dermatology, 2021, 84, 321-329.	0.6	26
665	Drug Development in Neuroendocrine Tumors: What Is on the Horizon?. Current Treatment Options in Oncology, 2021, 22, 43.	1.3	8
666	Cerebral metastasis of Merkel cell carcinoma following resection with negative margins and adjuvant external beam radiation: a case report. Journal of Medical Case Reports, 2021, 15, 118.	0.4	3

#	ARTICLE	IF	CITATIONS
667	Clinical Outcomes, Costs, and Healthcare Resource Utilization in Patients with Metastatic Merkel Cell Carcinoma Treated with Immune Checkpoint Inhibitors vs Chemotherapy. ClinicoEconomics and Outcomes Research, 2021, Volume 13, 213-226.	0.7	1
668	Case Report: Favorable Response to the Tyrosine Kinase Inhibitor Apatinib in Recurrent Merkel Cell Carcinoma. Frontiers in Oncology, 2021, 11, 625360.	1.3	3
669	Long-Term Remission with Ipilimumab/Nivolumab in Two Patients with Different Soft Tissue Sarcoma Subtypes and No PD-L1 Expression. Case Reports in Oncology, 2021, 14, 459-465.	0.3	9
670	Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysis. Cancer Treatment Reviews, 2021, 94, 102168.	3.4	6
671	Exploiting Tumor Neoantigens to Target Cancer Evolution: Current Challenges and Promising Therapeutic Approaches. Cancer Discovery, 2021, 11, 1024-1039.	7.7	56
673	Adenovirus-Mediated Inducible Expression of a PD-L1 Blocking Antibody in Combination with Macrophage Depletion Improves Survival in a Mouse Model of Peritoneal Carcinomatosis. International Journal of Molecular Sciences, 2021, 22, 4176.	1.8	6
674	Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers. , 2021, 9, e001752.		34
675	A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609; High-grade neuroendocrine neoplasm cohort. Cancer, 2021, 127, 3194-3201.	2.0	48
676	Checkpoint Inhibitors in Checkmating Rare Cancers. Journal of Immunotherapy and Precision Oncology, 2021, , .	0.6	1
677	High TIL, HLA, and Immune Checkpoint Expression in Conventional High-Grade and Dedifferentiated Chondrosarcoma and Poor Clinical Course of the Disease. Frontiers in Oncology, 2021, 11, 598001.	1.3	3
678	"Present and future of immunotherapy in Neuroendocrine Tumors". Reviews in Endocrine and Metabolic Disorders, 2021, 22, 615-636.	2.6	21
679	Clinical impact of immunotherapy in Merkel cell carcinoma patients: A systematic review and meta-analysis. Journal of the American Academy of Dermatology, 2022, 87, 121-130.	0.6	7
680	Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2021, 11, 650292.	1.3	22
681	Resistance mechanisms to checkpoint inhibitors. Current Opinion in Immunology, 2021, 69, 47-55.	2.4	19
682	Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. , 2021, 9, e002478.		59
683	How we treat Merkel cell carcinoma: within and beyond current guidelines. Future Oncology, 2021, 17, 1363-1377.	1.1	23
684	Serum alanine aminotransferase as an early marker of outcomes in patients receiving anti-PD-1 or anti-CTLA-4 antibody. Scientific Reports, 2021, 11, 10264.	1.6	0
685	Immunotherapy in advanced Merkel cell carcinoma: Sydney west cancer network experience. Journal of Medical Imaging and Radiation Oncology, 2021, 65, 760-767.	0.9	4

#	ARTICLE	IF	CITATIONS
686	Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review. <i>Frontiers in Oncology</i> , 2021, 11, 621639.	1.3	12
687	The Role of Programmed Death-1 in Type 1 Diabetes. <i>Current Diabetes Reports</i> , 2021, 21, 20.	1.7	11
688	Neurological complications of immune checkpoint inhibitor cancer immunotherapy. <i>Journal of the Neurological Sciences</i> , 2021, 424, 117424.	0.3	14
689	Prognostic Role of Tumoral PD-L1 and IDO1 Expression, and Intratumoral CD8+ and FoxP3+ Lymphocyte Infiltrates in 132 Primary Cutaneous Merkel Cell Carcinomas. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5489.	1.8	7
690	Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome. <i>Clinical and Translational Oncology</i> , 2021, 23, 2237-2252.	1.2	7
691	Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors: Current Management and Future Directions. <i>Cancers</i> , 2021, 13, 2448.	1.7	13
692	Immunotherapy and Gene Therapy for Oncoviruses Infections: A Review. <i>Viruses</i> , 2021, 13, 822.	1.5	3
693	PD-L1 combined with HDAC9 is a useful prognostic predictor in hepatocellular carcinoma. <i>Translational Cancer Research</i> , 2021, 10, 2305-2317.	0.4	3
694	Systemic Therapy for Head and Neck Skin Cancers. <i>Face</i> , 2021, 2, 121-130.	0.1	0
695	Checkpoint blockade accelerates a novel switch from an NKT-driven TNF α response toward a T cell driven IFN- γ response within the tumor microenvironment. , 2021, 9, e002269.		2
696	Merkel Cell Carcinoma. <i>Biomedicines</i> , 2021, 9, 718.	1.4	15
698	Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors. <i>Journal of Hematology and Oncology</i> , 2021, 14, 100.	6.9	21
699	The case of acute psychotic episode treatment in patient with myasthenia gravis. <i>Global Journal of Medical and Clinical Case Reports</i> , 2021, , 063-064.	0.0	0
700	Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6305.	1.8	20
701	Merkel cell carcinoma of the head and neck in the south-east of England. <i>British Journal of Oral and Maxillofacial Surgery</i> , 2021, , .	0.4	2
703	Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours. <i>BMI Open</i> . 2021. 11. e044543.	0.8	3
704	Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples. <i>Frontiers in Immunology</i> , 2021, 12, 599207.	2.2	18
705	RF- Immunotherapy in Merkel Cell Carcinoma. <i>Actas Dermo-sifiligráficas</i> , 2021, 112, 553-555.	0.2	0

#	ARTICLE	IF	CITATIONS
706	Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd,) Tj ETQq0 0.0 rgBT /Overlock 10	1.8	1
707	Ovarian Cancer Immunotherapy and Personalized Medicine. International Journal of Molecular Sciences, 2021, 22, 6532.	1.8	128
708	Complete response of merkel cell carcinoma with brain metastases to pembrolizumab and radiotherapy: A case report. Global Journal of Medical and Clinical Case Reports, 2021, , 059-062.	0.0	1
709	Imbalance of TGF- β 1/BMP-7 pathways induced by M2-polarized macrophages promotes hepatocellular carcinoma aggressiveness. Molecular Therapy, 2021, 29, 2067-2087.	3.7	42
710	Cancer Immunotherapies: From Efficacy to Resistance Mechanisms – Not Only Checkpoint Matters. Frontiers in Immunology, 2021, 12, 690112.	2.2	42
711	Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?. Cancers, 2021, 13, 3415.	1.7	15
712	Extended T-Cell Epitope Landscape in Merkel Cell Polyomavirus Large T and Small T Oncoproteins Identified Uniquely in Patients with Cancer. Journal of Investigative Dermatology, 2022, 142, 239-243.e13.	0.3	3
713	<scp>Real-World</scp>Clinical Outcomes in Patients with Locally Advanced or Metastatic Merkel Cell Carcinoma Treated in U.S. Oncology Clinical Practices: Results from <scp>SPEAR-Merkel</scp>. Oncologist, 2021, 26, e1633-e1643.	1.9	4
714	Selective Inhibition of Aurora Kinase A by AK-01/LY3295668 Attenuates MCC Tumor Growth by Inducing MCC Cell Cycle Arrest and Apoptosis. Cancers, 2021, 13, 3708.	1.7	3
715	Neuroendocrine Carcinomas of the Digestive Tract: What Is New?. Cancers, 2021, 13, 3766.	1.7	10
716	An analysis of the use of targeted therapies in patients with advanced Merkel cell carcinoma and an evaluation of genomic correlates of response. Cancer Medicine, 2021, 10, 5889-5896.	1.3	10
717	Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis. Journal of Hepatology, 2021, 75, 177-189.	1.8	29
718	Genomic, Microbial and Immunological Microenvironment of Colorectal Polyps. Cancers, 2021, 13, 3382.	1.7	7
720	Systemic immune-inflammation index is a stage-dependent prognostic factor in patients with operable non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 3144-3154.	1.3	15
721	Merkel Cell Carcinoma of the Head and Neck: Epidemiology, Pathogenesis, Current State of Treatment and Future Directions. Cancers, 2021, 13, 3506.	1.7	8
722	Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health. Oncologist, 2021, 26, e1786-e1799.	1.9	52
723	T-Cell Responses in Merkel Cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic Options. International Journal of Molecular Sciences, 2021, 22, 8679.	1.8	3
724	Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). , 2021, 9, e002990.		58

#	ARTICLE	IF	CITATIONS
725	Bioinformatics Analysis of Merkel Cell Carcinoma to identify critical genes and their validation. Asian Journal of Convergence in Technology, 2021, 7, 19-24.	0.2	0
726	<scp>Real-World</scp> Clinical and Economic Outcomes in Selected <scp>Immune-Related</scp> Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors. Oncologist, 2021, 26, e2002-e2012.	1.9	11
727	Quality Is King: Fundamental Insights into Tumor Antigenicity from Virus-Associated Merkel Cell Carcinoma. Journal of Investigative Dermatology, 2021, 141, 1897-1905.	0.3	6
728	Macrophages and fibroblasts underpin skin immune responses. Exploration of Immunology, 0, , 226-242.	1.7	2
729	Immunotherapy for Non-melanoma Skin Cancer. Current Oncology Reports, 2021, 23, 125.	1.8	49
730	Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale?. Frontiers in Oncology, 2021, 11, 739006.	1.3	12
731	PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia/Lymphoma. International Immunopharmacology, 2021, 98, 107870.	1.7	13
732	The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2427-2435.	1.2	5
733	Tâ€œcell subsets in the skin and their role in inflammatory skin disorders. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 827-842.	2.7	27
734	Immune PET Imaging. Radiologic Clinics of North America, 2021, 59, 875-886.	0.9	2
735	The Association of Radiation Therapy and Chemotherapy on Overall Survival in Merkel Cell Carcinoma: A Population-Based Analysis. Cureus, 2021, 13, e18276.	0.2	1
736	Cardiotoxicity in cancer immune-checkpoint therapy: Mechanisms, clinical evidence, and management strategies. International Journal of Cardiology, 2021, 344, 170-178.	0.8	13
737	BIO-ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF AVELUMAB, AXITINIB AND ITS APPLICATION TO PHARMACOKINETIC STUDIES IN RABBIT PLASMA BY USING LCMS/MS. International Journal of Applied Pharmaceutics, 0, , 198-204.	0.3	0
738	Cells to Surgery Quiz: September 2021. Journal of Investigative Dermatology, 2021, 141, e111-e117.	0.3	0
739	Merkel Cell Carcinoma: Changing Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally. Annals of Surgical Oncology, 2022, 29, 415-424.	0.7	4
740	Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629. Dermatology and Therapy, 2021, 11, 1777-1790.	1.4	8
741	Multimodal Strategy in Localized Merkel Cell Carcinoma: Where Are We and Where Are We Heading?. International Journal of Molecular Sciences, 2021, 22, 10629.	1.8	3
743	Recent advances in immune checkpoint therapy in non-small cell lung cancer and opportunities for nanoparticle-based therapy. European Journal of Pharmacology, 2021, 909, 174404.	1.7	18

#	ARTICLE	IF	CITATIONS
744	Viral infections and the efficacy of PD-(L)1 inhibitors in virus-related cancers: Head and neck squamous cell carcinoma and hepatocellular carcinoma. <i>International Immunopharmacology</i> , 2021, 100, 108128.	1.7	13
745	Atypical Skin Lesions. , 2022, , 114-130.		0
746	TLRs as a Promise Target Along With Immune Checkpoint Against Gastric Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 611444.	1.8	24
747	Sex Differences in Overall Survival and the Effect of Radiotherapy in Merkel Cell Carcinomaâ€”A Retrospective Analysis of A Swedish Cohort. <i>Cancers</i> , 2021, 13, 265.	1.7	8
748	Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2087-2093.	2.0	29
749	Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199299.	1.4	20
750	Biomarkers: Is Tumor Mutational Burden the New Prognostic Grail?. <i>Current Cancer Research</i> , 2021, , 27-54.	0.2	0
751	Epidemiology and Retrospective Analysis in Extrapulmonary Neuroendocrine Carcinoma. <i>Cureus</i> , 2021, 13, e12748.	0.2	1
752	Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 277-285.	0.8	9
753	Skin Neuroendocrine Neoplasms. , 2021, , 335-356.		1
754	Rational Discovery of Response Biomarkers: Candidate Prognostic Factors and Biomarkers for Checkpoint Inhibitor-Based Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 143-166.	0.8	3
755	The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer. <i>BioDrugs</i> , 2020, 34, 495-503.	2.2	15
756	Inmunoterapia en cÃ¡ncer cutÃ¡neo no melanoma. <i>Actas Dermo-sifiligrÃ¡ficas</i> , 2019, 110, 353-359.	0.2	4
757	Immune checkpoint inhibitors to treat cutaneous malignancies. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1239-1253.	0.6	56
758	Dramatic enhancement of the detection limits of bioassays via ultrafast deposition of polydopamine. <i>Nature Biomedical Engineering</i> , 2017, 1, .	11.6	93
759	p110Î³ PI3K as a therapeutic target of solid tumours. <i>Clinical Science</i> , 2020, 134, 1377-1397.	1.8	15
760	Immune Checkpoint Inhibitors in Transplantationâ€”A Case Series and Comprehensive Review of Current Knowledge. <i>Transplantation</i> , 2021, 105, 67-78.	0.5	21
765	Advanced Merkel cell carcinomaâ€”A focus on medical drug therapy. <i>Dermatologic Therapy</i> , 2020, 33, e13675.	0.8	3

#	ARTICLE	IF	CITATIONS
766	Tuberculosis following PD-1 blockade for cancer immunotherapy. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	141
767	Metastatic Merkel-cell carcinoma: the dawn of a new era. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2018-224924.	0.2	2
768	Glucose-6-phosphate dehydrogenase correlates with tumor immune activity and programmed death ligand-1 expression in Merkel cell carcinoma. , 2020, 8, e001679.		13
769	Endogenous retrovirus expression is associated with response to immune checkpoint pathway in clear cell renal cell carcinoma. <i>JCI Insight</i> , 2018, 3, .	2.3	128
770	Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma. <i>Journal of Clinical Investigation</i> , 2020, 130, 5833-5846.	3.9	58
771	Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. <i>Journal of Clinical Investigation</i> , 2018, 128, 1338-1354.	3.9	64
772	Clinical Benefit from Tyrosine Kinase Inhibitors in Metastatic Merkel Cell Carcinoma: A Case Series of 5 Patients. <i>American Journal of Case Reports</i> , 2018, 19, 505-511.	0.3	29
773	Recent advances in HIV-associated Kaposi sarcoma. <i>F1000Research</i> , 2019, 8, 970.	0.8	24
774	Recent advances in understanding antitumor immunity. <i>F1000Research</i> , 2016, 5, 2545.	0.8	29
775	Avelumab for the treatment of metastatic Merkel cell carcinoma. <i>Drugs of Today</i> , 2017, 53, 377.	0.7	6
776	Common Commensal Cancer Viruses. <i>PLoS Pathogens</i> , 2017, 13, e1006078.	2.1	29
777	Neutron Radiation Therapy for Treatment of Refractory Merkel Cell Carcinoma. <i>International Journal of Particle Therapy</i> , 2017, 3, 485-491.	0.9	7
778	Does Neutron Radiation Therapy Potentiate an Immune Response to Merkel Cell Carcinoma?. <i>International Journal of Particle Therapy</i> , 2018, 5, 183-195.	0.9	15
779	<scp>LSD</scp>1 inhibition induces differentiation and cell death in Merkel cell carcinoma. <i>EMBO Molecular Medicine</i> , 2020, 12, e12525.	3.3	41
780	Targeting the epigenetic addiction of Merkel cell carcinoma. <i>EMBO Molecular Medicine</i> , 2020, 12, e13347.	3.3	4
781	Unveiling kaposi sarcoma viral antigens. <i>Oncotarget</i> , 2017, 8, 50325-50326.	0.8	1
782	Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe. <i>Oncotarget</i> , 2017, 8, 79731-79741.	0.8	77
783	Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer. <i>Oncotarget</i> , 2018, 9, 5652-5664.	0.8	105

#	ARTICLE	IF	CITATIONS
784	PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours. <i>Oncotarget</i> , 2018, 9, 14922-14938.	0.8	29
785	Sustained partial remission of a metastatic NEN using off-label immunotherapy with pembrolizumab. <i>Oncotarget</i> , 2019, 10, 3302-3311.	0.8	6
786	Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies. <i>Oncotarget</i> , 2020, 11, 600-618.	0.8	15
787	Immune Checkpoint Inhibitor Can Reduce HCV-RNA without Liver Damage. <i>Internal Medicine</i> , 2020, 59, 2245-2248.	0.3	6
788	Immune Blockade Inhibition in Breast Cancer. <i>Anticancer Research</i> , 2016, 36, 5607-5622.	0.5	37
789	Phospho-STAT5B Expression Is a Prognostic Marker for Merkel Cell Carcinoma. <i>Anticancer Research</i> , 2017, 37, 2335-2341.	0.5	5
790	Clinical Significance of PD1 and PDL1 in Human Breast Cancer. <i>Anticancer Research</i> , 2017, 37, 4249-4254.	0.5	26
791	Updates to Clinical Information on Anticancer Immunotherapy. <i>Korean Journal of Clinical Pharmacy</i> , 2018, 28, 65-75.	0.0	3
792	Is There a Place for Immune Checkpoint Inhibitors in Vulvar Neoplasms? A State of the Art Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 190.	1.8	31
793	Cardiotoxicity of FDA-approved immune checkpoint inhibitors: A rare but serious adverse event. <i>Journal of Immunotherapy and Precision Oncology</i> , 2018, 1, 68-77.	0.6	8
794	Cancer systems immunology. <i>ELife</i> , 2020, 9, .	2.8	14
795	Cutaneous Melanoma and Other Skin Cancers. <i>UNIPA Springer Series</i> , 2021, , 979-1007.	0.1	0
796	Scientific and clinical developments in Merkel cell carcinoma: A polyomavirus-driven, often-lethal skin cancer. <i>Journal of Dermatological Science</i> , 2022, 105, 2-10.	1.0	10
797	Nanomedicine for Immunotherapy Targeting Hematological Malignancies: Current Approaches and Perspective. <i>Nanomaterials</i> , 2021, 11, 2792.	1.9	8
798	Immunotherapy of cancer tumors with inhibition of PD-1 membrane protein and its ligands interaction. <i>Acta Biomedica Scientifica</i> , 2021, 6, 146-159.	0.1	0
799	Immune Response in Myocardial Injury: In Situ Hybridization and Immunohistochemistry Techniques for SARS-CoV-2 Detection in COVID-19 Autopsies. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 658932.	1.6	5
800	Profiling immune-evasion pathways in a Merkel cell carcinoma (MCC). <i>Human Pathology Reports</i> , 2021, 26, 300561.	0.1	0
801	Therapy for Metastatic Disease: Stomach/Duodenum, Colon/Rectum. , 2018, , 277-293.		0

#	ARTICLE	IF	CITATIONS
803	Carcinome de Merkel : actualités physiopathologiques et thérapeutiques. <i>Oncologie</i> , 2018, 20, 19-26.	0.2	1
804	A Case of Merkel Cell Carcinoma of the Lymph Node in the Parotid Gland with Spontaneous Regression of the Skin Lesion. <i>Practica Otologica</i> , 2018, 111, 571-576.	0.0	0
805	Immune Checkpoint Inhibition. , 2018, , 315-353.		0
806	Chemotherapy for Temporal Bone Cancer. , 2018, , 403-410.		0
808	Enjeux et difficultés de la gestion des médicaments oncoeux non intégrés dans la liste en sus pour un hôpital traitant des cancers. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2018, 202, 1003-1012.	0.0	0
811	Melanom. , 2019, , 45-134.		0
812	Sentinel Lymph Node Biopsy for Eyelid and Conjunctival Malignancies. , 2019, , 261-277.		0
813	Andere Tumoren. , 2019, , 191-239.		0
815	Avelumab in the treatment of patients with merkel cell carcinoma: initial results of early access program in Russia. <i>Malignant Tumours</i> , 2019, 9, 53-58.	0.1	1
816	Palliative Systemic Treatment of Advanced Merkel Cell Carcinoma in the Pre-Immunotherapy Era: A Retrospective, Single-Center Analysis of Patients with An Orphan Neuroendocrine Malignancy. <i>Oncogen</i> , 2019, 2, .	0.3	0
817	Systemic Treatment for Metastatic or Recurrent Disease. , 2020, , 275-287.		0
820	Prognostic and predictive role of the tumor immune landscape. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 143-151.	0.4	3
821	Avelumab for the treatment of patients with Merkel cell carcinoma. <i>Meditinskiy Sovet</i> , 2020, , 94-100.	0.1	0
822	Merkel cell carcinoma (neuroendocrine carcinoma of the skin): a lecture with a brief overview of 19 cases and demonstration of two clinical observations. <i>Almanah Klinicheskoj Mediciny</i> , 2020, 48, 125-139.	0.2	1
823	Patient Resources in a Cancer Center. , 2022, , 145-155.		0
824	New interpretable machine-learning method for single-cell data reveals correlates of clinical response to cancer immunotherapy. <i>Patterns</i> , 2021, 2, 100372.	3.1	22
826	Inhibition of T-antigen expression promoting glycogen synthase kinase 3 impairs merkel cell carcinoma cell growth. <i>Cancer Letters</i> , 2022, 524, 259-267.	3.2	8
827	Merkel cell carcinoma in Turkey: A multicentric study. <i>Journal of Cancer Research and Therapeutics</i> , 2021, 17, 1525.	0.3	0

#	ARTICLE	IF	CITATIONS
829	Merkel Cell Polyomavirus (MCPyV). Encyclopedia of Pathology, 2020, , 1-8.	0.0	0
830	Eyelid and Periocular Cutaneous Carcinomas. , 2020, , 1-38.		0
831	Non-melanoma Skin Cancer and Cutaneous Melanoma from the Oncological Point of View. , 2020, , 41-68.		0
833	Metastatic Merkel Cell Carcinoma of the Abdominal Wall. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 275-279.	0.1	0
834	FEATURES OF THE COURSE OF METASTASES FROM MERKEL CELLS. Ukrainian Journal of Radiology and Oncology, 2020, 28, 67-72.	0.2	0
835	Immune Cell Infiltration Landscape of Ovarian Cancer to Identify Prognosis and Immunotherapy-Related Genes to Aid Immunotherapy. Frontiers in Cell and Developmental Biology, 2021, 9, 749157.	1.8	6
836	The viral expression and immune status in human cancers and insights into novel biomarkers of immunotherapy. BMC Cancer, 2021, 21, 1183.	1.1	5
837	Merkel Cell Polyomavirus and Human Merkel Cell Carcinoma. Recent Results in Cancer Research, 2021, 217, 303-323.	1.8	3
838	Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2017 MauiDerm Meeting. Journal of Clinical and Aesthetic Dermatology, 2017, 10, S8-S41.	0.1	2
840	Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma. Aging, 2020, 12, 22509-22526.	1.4	4
841	Biomarker-Driven Prognostication in Merkel Cell Carcinoma: A Paradigm for Personalized Therapy. Annals of Surgical Oncology, 2021, , 1.	0.7	1
842	Immune activity in Merkel cell carcinoma. Journal of Dermatology, 2021, 49, 68.	0.6	2
843	Sudden and severe cardiotoxicity induced with pembrolizumab, its clinical course, therapeutic intervention, and outcome. International Cancer Conference Journal, 2022, 11, 81-86.	0.2	2
844	An Extremely Rare Case of Metastatic Merkel Carcinoma of the Liver. Cureus, 2021, 13, e19659.	0.2	0
845	Merkel Cell Polyomavirus Antibody Titer Predicts Recurrence-Free Survival. Annals of Surgical Oncology, 2022, 29, 1620-1626.	0.7	4
846	Communication pathways bridge local and global conformations in an IgG4 antibody. Scientific Reports, 2021, 11, 23197.	1.6	5
847	Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity. Advances in Experimental Medicine and Biology, 2021, 1342, 377-387.	0.8	2
848	External stimuli-responsive nanomedicine for cancer immunotherapy. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
849	Merkel cell carcinoma: An updated review of pathogenesis, diagnosis, and treatment options. <i>Dermatologic Therapy</i> , 2022, 35, e15292.	0.8	20
850	Immunotherapy in skin cancers - A narrative review. <i>Journal of Skin and Sexually Transmitted Diseases</i> , 0, .	0.0	0
851	Effects of ESCO2 or its methylation on the prognosis, clinical characteristics, immune microenvironment, and pathogenesis of low-grade glioma. <i>International Immunopharmacology</i> , 2022, 104, 108399.	1.7	1
852	Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma. <i>Aging</i> , 2020, 12, 22509-22526.	1.4	7
853	Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma. , 2022, 10, e003198.		21
854	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). <i>Annals of Surgical Oncology</i> , 2022, 29, 3694-3708.	0.7	21
855	Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3182-3192.	1.1	4
856	Histone Acetylation Regulator-Mediated Acetylation Patterns Define Tumor Malignant Pathways and Tumor Microenvironment in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2022, 13, 761046.	2.2	19
857	Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 798474.	2.2	10
858	PD-L1 in circulating exosomes of Merkel cell carcinoma. <i>Experimental Dermatology</i> , 2022, 31, 869-877.	1.4	6
859	Antibody-Drug Conjugates as an Emerging Therapy in Oncodermatology. <i>Cancers</i> , 2022, 14, 778.	1.7	13
860	Immunotherapy for Nonmelanoma Skin Cancer: Facts and Hopes. <i>Clinical Cancer Research</i> , 2022, 28, 2211-2220.	3.2	23
861	Advances in Immunology: A Cornerstone in Diagnosis and Therapy of Merkel Cell Carcinoma. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2022, 10, 232470962210894.	0.3	2
862	Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. , 2022, 10, e003026.		38
863	Merkel cell carcinoma brain metastasis with radiological findings mimicking primary CNS lymphoma: illustrative case. <i>Journal of Neurosurgery Case Lessons</i> , 2022, 3, .	0.1	1
864	Editorial to the Special Issue on Skin Cancer: The State of the Art. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3806.	1.8	0
865	Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 827921.	2.2	43
866	Current Clinical Trial Landscape of OX40 Agonists. <i>Current Oncology Reports</i> , 2022, 24, 951-960.	1.8	15

#	ARTICLE	IF	CITATIONS
867	Pembrolizumab Compared with Standard-of-Care Observation in Treating Patients with Completely Resected Stage III Merkel Cell Cancer (STAMP). <i>Annals of Surgical Oncology</i> , 2022, 29, 3379-3380.	0.7	2
868	CMTM6 as a master regulator of PD-L1. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2325-2340.	2.0	7
869	Merkel Cell Carcinoma with Gastric Metastasis, a Rare Presentation: Case Report and Literature Review. <i>Journal of Gastrointestinal Cancer</i> , 2023, 54, 309-315.	0.6	0
870	Targeting cancer-associated glycans as a therapeutic strategy in leukemia. <i>International Journal of Transgender Health</i> , 2022, 15, 378-433.	1.1	2
871	The clinical and prognostic significance of CMTM6/PD-L1 in oncology. <i>Clinical and Translational Oncology</i> , 2022, 24, 1478-1491.	1.2	2
872	The Role of Histone Post-Translational Modifications in Merkel Cell Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 832047.	1.3	30
873	Ovarian Endometrioid and Clear Cell Carcinomas with Low Prevalence of Microsatellite Instability: A Unique Subset of Ovarian Carcinomas Could Benefit from Combination Therapy with Immune Checkpoint Inhibitors and Other Anticancer Agents. <i>Healthcare (Switzerland)</i> , 2022, 10, 694.	1.0	4
874	PD-1 blockade with pembrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2022, 23, 491-500.	5.1	20
875	CAR-T Cells for the Treatment of Lung Cancer. <i>Life</i> , 2022, 12, 561.	1.1	8
876	Case Report: Cardiac Toxicity Associated With Immune Checkpoint Inhibitors. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 727445.	1.1	7
877	Merkel Cell Carcinoma: Evaluation of the Clinico-Pathological Characteristics, Treatment Strategies and Prognostic Factors in a Monocentric Retrospective Series (n=143). <i>Frontiers in Oncology</i> , 2021, 11, 737842.	1.3	6
878	Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges. <i>Cancers</i> , 2022, 14, 109.	1.7	21
879	Single-Molecule RNA Sequencing Reveals IFN γ -Induced Differential Expression of Immune Escape Genes in Merkel Cell Polyomavirus-Positive MCC Cell Lines. <i>Frontiers in Microbiology</i> , 2021, 12, 785662.	1.5	1
880	Immune Checkpoint Inhibition in Non-Melanoma Skin Cancer: A Review of Current Evidence. <i>Frontiers in Oncology</i> , 2021, 11, 734354.	1.3	17
881	Anti-PD-1 therapy using cemiplimab for advanced cutaneous squamous cell carcinoma in HIV patient: A case report. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e05228.	0.2	2
882	An Unusual Cause of AKI in a Kidney Transplant Patient with Merkel Cell Cancer. <i>Kidney360</i> , 2021, 2, 2040-2041.	0.9	1
883	Molecular profiling of breast and lung cancer in women with HIV reveals high tumor mutational burden. <i>Aids</i> , 2022, 36, 567-571.	1.0	3
884	An update on local and systemic therapies for nonmelanoma skin cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 479-489.	1.1	2

#	ARTICLE	IF	CITATIONS
897	Eyelid and Periocular Cutaneous Carcinomas. , 2022, , 5483-5520.		0
898	The efficacy of immune checkpoint inhibitors in rare tumors: A systematic review of published clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 174, 103700.	2.0	6
899	Avelumab in unresectable/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials. <i>European Journal of Cancer</i> , 2022, 169, 74-81.	1.3	15
900	Response to comment on "Merkel cell carcinoma: An updated review of pathogenesis, diagnosis, and treatment options." <i>Dermatologic Therapy</i> , 2022, , e15581.	0.8	0
902	Head and Neck Merkel Cell Carcinoma: A 12-Year Single Institutional Experience. <i>JPRAS Open</i> , 2022, 33, 161-170.	0.4	0
903	Characterization of clinical outcomes after shorter course hypofractionated and standard-course radiotherapy for stage I-III curatively-treated Merkel cell carcinoma. <i>Radiotherapy and Oncology</i> , 2022, 173, 32-40.	0.3	5
904	Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma. , 2022, 10, e004839.		4
905	Merkel cell carcinoma of the eyelid and periocular region: A review. <i>Saudi Journal of Ophthalmology</i> , 2021, 35, 186.	0.3	4
906	Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer. <i>Molecules</i> , 2022, 27, 3798.	1.7	29
907	Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	4
908	Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 529-540.	21.5	134
909	Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response. <i>Journal of Clinical Medicine</i> , 2022, 11, 3364.	1.0	20
910	Talimogene laherparepvec resulting in near-complete response in a patient with treatment-refractory Merkel cell carcinoma. <i>Australasian Journal of Dermatology</i> , 2022, 63, .	0.4	3
911	Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline " Update 2022. <i>European Journal of Cancer</i> , 2022, 171, 203-231.	1.3	51
912	ICIs-Related Cardiotoxicity in Different Types of Cancer. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 203.	0.8	11
913	Merkel cell carcinoma of the anorectum: a case report and review of the literature. <i>Clinical Journal of Gastroenterology</i> , 0, , .	0.4	0
914	Tumor immunotherapy: Mechanisms and clinical applications. , 2022, 1, .		2
915	Primary pulmonary lymphoepithelioma-like carcinoma treated with immunotherapy: A case report and literature review. <i>Thoracic Cancer</i> , 0, , .	0.8	4

#	ARTICLE	IF	CITATIONS
916	The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7839.	1.8	13
917	Incidence of immune checkpoint inhibitor mediated cardiovascular toxicity: A systematic review and meta-analysis. <i>European Journal of Clinical Investigation</i> , 2022, 52, .	1.7	7
918	Routine Screening for Central and Primary Adrenal Insufficiency during Immune-Checkpoint Inhibitor Therapy: An Endocrinology Perspective for Oncologists. <i>Current Oncology</i> , 2022, 29, 4665-4677.	0.9	7
919	Comorbid immunosuppression in Merkel cell carcinoma: A retrospective database study. <i>JAAD International</i> , 2022, 8, 136-138.	1.1	1
920	A Retrospective Study of Ipilimumab Plus Nivolumab in Anti-PD-L1/PD-1 Refractory Merkel Cell Carcinoma. <i>Journal of Immunotherapy</i> , 2022, 45, 299-302.	1.2	13
921	Application of immune enhanced organoids in modeling personalized Merkel cell carcinoma research. <i>Scientific Reports</i> , 2022, 12, .	1.6	8
922	Dataset for the Reporting of Merkel Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 0, Publish Ahead of Print, .	2.1	1
923	T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8590.	1.8	12
924	The Role of Pathology-Based Methods in Qualitative and Quantitative Approaches to Cancer Immunotherapy. <i>Cancers</i> , 2022, 14, 3833.	1.7	4
925	Image-guided intratumoral immunotherapy: Developing a clinically practical technology. <i>Advanced Drug Delivery Reviews</i> , 2022, 189, 114505.	6.6	15
926	Significant response to Pembrolizumab for metastatic cutaneous squamous cell carcinoma in patient with Netherton syndrome. <i>Annals of Medicine and Surgery</i> , 2022, 81, .	0.5	0
927	Early evaluation of subclinical cardiotoxicity in patients with lung cancer receiving immune checkpoint inhibitors by cardiovascular magnetic resonance: a prospective observational study. <i>Quantitative Imaging in Medicine and Surgery</i> , 2022, 12, 4771-4785.	1.1	2
928	Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma. , 2022, 10, e005328.		6
929	First-line treatment of camrelizumab combined with chemotherapy in advanced gastroenteropancreatic neuroendocrine carcinoma: Study protocol for a prospective, multicenter, phase II study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
930	Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer. , 2022, 10, e005128.		4
931	Immune-related 3-lncRNA signature with prognostic connotation in a multi-cancer setting. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	5
932	Antibody-Drug Conjugates for Melanoma and Other Skin Malignancies. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1428-1442.	1.3	1
933	Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial. <i>Lancet, The</i> , 2022, 400, 1008-1019.	6.3	48

#	ARTICLE	IF	CITATIONS
934	ãf;ãf«ã,±ãf«ç°èfžãfãfã,ãf¼ãfžã, ã,ãf«ã,¹. Skin Cancer, 2022, 37, 79-83.	0.1	1
936	A Regional Survey on Merkel Cell Carcinoma: A Plea for Uniform Patient Journey Modeling and Diagnosticâ€“Therapeutic Pathway. Current Oncology, 2022, 29, 7229-7244.	0.9	2
937	Current In Vitro and In Vivo Models to Study MCPyV-Associated MCC. Viruses, 2022, 14, 2204.	1.5	5
938	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. Journal of Hematology and Oncology, 2022, 15, .	6.9	59
940	Current Status of Immune Checkpoint Inhibitors. Nihon Kikan Shokudoka Gakkai Kaiho, 2022, 73, 303-307.	0.0	0
942	The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. Life Sciences, 2022, 310, 121138.	2.0	14
943	A Review of Immune Checkpoint Blockade for the General Surgeon. Journal of Surgical Research, 2023, 281, 289-298.	0.8	3
944	Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas. Frontiers in Oncology, 0, 12, .	1.3	3
945	Best practices in surgical and nonsurgical management of head and neck Merkel cell carcinoma: An update. Molecular Carcinogenesis, 2023, 62, 101-112.	1.3	4
946	Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management. Frontiers in Immunology, 0, 13, .	2.2	5
948	Merkel Cell Carcinoma of the External Ear: Population-Based Analysis and Survival Outcomes. Cancers, 2022, 14, 5653.	1.7	2
949	Identification of Immunogenic Cell Death-Related Signature for Glioma to Predict Survival and Response to Immunotherapy. Cancers, 2022, 14, 5665.	1.7	1
950	Stability and Hopf bifurcation of a tumorâ€“immune system interaction model with an immune checkpoint inhibitor. Communications in Nonlinear Science and Numerical Simulation, 2023, 118, 106996.	1.7	3
951	Merkel Cell Polyomavirus (MCPyV). Encyclopedia of Pathology, 2022, , 499-506.	0.0	0
952	A Random Forest Genomic Classifier for Tumor Agnostic Prediction of Response to Anti-PD1 Immunotherapy. Cancer Informatics, 2022, 21, 117693512211360.	0.9	1
953	Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG. , 2022, 10, e005930.		10
954	Management and Prognosis of Cardiac Metastatic Merkel Cell Carcinoma: A Caseâ€“Control Study and Literature Review. Cancers, 2022, 14, 5914.	1.7	2
955	Lower Extremity Edema and Lesions Not Responsive to Conservative Therapy. AACE Clinical Case Reports, 2022, , .	0.4	1

#	ARTICLE	IF	CITATIONS
956	TGF- β 2: A novel predictor and target for anti-PD-1/PD-L1 therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	22
957	Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates. <i>International Journal of Molecular Sciences</i> , 2023, 24, 41.	1.8	6
958	T-Cell Mediated Immunity in Merkel Cell Carcinoma. <i>Cancers</i> , 2022, 14, 6058.	1.7	2
959	Merkel Cell Carcinomaâ€”Update on Diagnosis, Management and Future Perspectives. <i>Cancers</i> , 2023, 15, 103.	1.7	9
960	The Current Management of Merkel Carcinoma of the Head and Neck: a Scoping Review. <i>SN Comprehensive Clinical Medicine</i> , 2023, 5, .	0.3	0
961	CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities. <i>Vaccines</i> , 2023, 11, 165.	2.1	9
962	Role of B7 family members in glioma: Promising new targets for tumor immunotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
963	Merkel cell carcinoma: a forty-year experience at the Peter MacCallum Cancer Centre. <i>BMC Cancer</i> , 2023, 23, .	1.1	3
964	Immunopathogenesis of Immune Checkpoint Inhibitor Induced Myocarditis: Insights from Experimental Models and Treatment Implications. <i>Biomedicines</i> , 2023, 11, 107.	1.4	4
965	Baseline ultrasound and FDGâ€”PET/CT imaging in Merkel cell carcinoma. <i>Journal of Surgical Oncology</i> , 2023, 127, 841-847.	0.8	1
966	Dietary Considerations for Inflammatory Bowel Disease Are Useful for Treatment of Checkpoint Inhibitor-Induced Colitis. <i>Cancers</i> , 2023, 15, 84.	1.7	1
967	Epitheliale Tumore im Kopf-Hals-Bereich. , 2022, , 237-261.		0
968	Tumor immunology. , 2023, , 245-452.		0
970	Leading Edge: Intratumor Delivery of Monoclonal Antibodies for the Treatment of Solid Tumors. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2676.	1.8	6
971	Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients With Advanced Skin Cancersâ€”Emerging Strategies for Clinical Management. <i>Transplantation</i> , 2023, 107, 1452-1462.	0.5	7
972	Immunotherapies in rare cancers. <i>Molecular Cancer</i> , 2023, 22, .	7.9	15
973	BRCA1/2 Pathogenic Variants Are Not Common in Merkel Cell Carcinoma: Comprehensive Molecular Study of 30 Cases and Meta-Analysis of the Literature. <i>Journal of Investigative Dermatology</i> , 2023, 143, 1178-1186.	0.3	1
974	Neuroendocrine Tumors and Immune System. , 2023, , .		0

#	ARTICLE	IF	CITATIONS
975	Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
976	Future therapeutic strategies in the treatment of extrapulmonary neuroendocrine carcinoma: a review. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311568.	1.4	2
977	Merkel cell carcinoma: epidemiology, clinical features, diagnosis and treatment of a rare disease. <i>Anais Brasileiros De Dermatologia</i> , 2023, 98, 277-286.	0.5	3
978	Immunotherapy of Merkel Cell Carcinoma. , 2023, , 1-22.		0
979	Case report: combination of immune-related thrombocytopenia and myocarditis in 8 ^o patient treated with immune checkpoint inhibitors for non-small cell lung cancer. <i>Malignant Tumours</i> , 2023, 13, 24-29.	0.1	0
980	Merkel cell carcinoma: an update. <i>Human Pathology</i> , 2023, 140, 39-52.	1.1	4
981	S2k Guideline "Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) " Update 2022. <i>JDDG - Journal of the German Society of Dermatology</i> , 2023, 21, 305-320.	0.4	3
982	S2k-Leitlinie "Merkelzellkarzinom " Update 2022. <i>JDDG - Journal of the German Society of Dermatology</i> , 2023, 21, 305-317.	0.4	1
983	Deciphering the roles of myeloid derived suppressor cells in viral oncogenesis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
985	Promising Therapeutic Impact of Immune Checkpoint Inhibitors in Type II Endometrial Cancer Patients with Deficient Mismatch Repair Status. <i>Healthcare (Switzerland)</i> , 2023, 11, 1073.	1.0	0
986	Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
987	Early evaluation of severe immune checkpoint inhibitor-associated myocarditis: a real-world clinical practice. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	0
1001	Review of Merkel cell carcinoma with solitary pancreatic metastases mimicking primary neuroendocrine tumor of the pancreas. <i>Clinical Journal of Gastroenterology</i> , 0, , .	0.4	0
1012	Case Report: Stereotactic body radiation treatment for immunotherapy escaped oligometastatic progression in cutaneous melanoma and merkel cell carcinoma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1